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ABSTRACT 
Modeling the Long Term Effects of Alendronate on Bone Mass Preservation of 
the Femur with Articular Surface and Total Hip Replacements 
Trevor Hryce 
  
 Calculating femoral bone density changes after hip arthroplasty is of 
interest to researchers and clinicians for predicting the longevity of the prosthetic 
implant and the surrounding bone.  Recently clinicians have been administering 
bisphosphonate drugs in an attempt to reduce the bone resorption due to stress 
shielding caused by these implants.  Current strain-adaptive computational 
models with bisphosphonate treatment don’t predict the long term effects or look 
at treatment with hip resurfacing implants.  The main goal of this study was to 
create and validate a computer model of the human femur incorporating a bone 
remodeling algorithm based on biological remodeling processes and 
bisphosphonate drug treatment.  A secondary objective was to then create 
various bisphosphonate drug treatment scenarios and evaluate differences in 
bone density, damage, and activation frequency.  Experimental studies were 
used to validate the model and the effects of bisphosphonates.  A finite element 
model created from a CT scan of a cadaveric femur, a bone remodeling 
algorithm, and a bisphosphonate algorithm were incorporated into the model with 
loading conditions representative of walking and stair climbing.  The model was 
allowed to evolve from an initial state of homogenous density to a steady state 
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form with a density similar to that of the femur.  Reduced loading representative 
of decreased muscle forces were applied to the steady state form to simulate 
preoperative conditions of a patient with hip osteoarthritis.  Both a femoral hip 
resurfacing component and an uncemented, tapered stem were then integrated 
in the computer model representative of a postoperative state.  Bisphosphonate 
treatment was applied to both the preoperative and postoperative states in 
several scenarios after untreated simulations.  Bone loss was predicted over a 
six year postoperative period for both implants and varying treatments.  Femoral 
bone loss in bisphosphonate treatment scenarios matched results seen clinically.  
Bone volume fraction (BVF) showed little change between one year preoperative 
to one year postoperative Alendronate treatment and one year postoperative 
Alendronate treatment for a specific implant type. Both treatment scenarios 
increase the BVF over no treatment.  Pretreating with Alendronate appears to 
help against femoral neck fracture.  This study successfully created a three-
dimensional finite element model able to simulate long term effects of the 
remodeling process in bone with Alendronate treatment.  The results show an 
importance of treatment timing for both types of implants especially when 
potentially requiring a revision surgery. 
vi 
 
 
ACKNOWLEDGMENTS 
 
 I’d like to personally thank my advisor, Dr. Scott Hazelwood, for his 
participation and assistance with my research.  I could not have asked for a 
better advisor.  I’d also like to thank my family for their support while attending 
Cal Poly for the past five years.  Without them I wouldn’t have experienced the 
many opportunities Cal Poly provided.  Lastly I’d like to thank all my friends not 
mentioned who have given me help and also shown me support. 
vii 
 
 
Table of Contents 
List of Tables ...............................................................................................................................viii 
List of Figures................................................................................................................................ ix 
1. Introduction............................................................................................................................ 1 
1.1. Purpose .............................................................................................................. 1 
1.2. Bone Structure .................................................................................................. 2 
1.3. Bone Remodeling .............................................................................................. 5 
1.4. Osteoporosis ...................................................................................................... 6 
1.5. Bisphosphonates ............................................................................................... 8 
1.6. Osteoarthritis .................................................................................................. 11 
1.7. Hip Arthroplasty ............................................................................................ 12 
1.8. Previous Remodeling Simulations................................................................. 18 
1.9. Remodeling Algorithm................................................................................... 23 
1.10. Bisphosphonate Algorithm ............................................................................ 27 
1.11. Finite Element Analysis Modeling ................................................................ 28 
1.12. Current Model ................................................................................................ 29 
2. Methods ................................................................................................................................ 36 
2.1. Model Recreation............................................................................................ 36 
2.2. Model Incorporation and Validation............................................................ 36 
2.3. Alendronate Code........................................................................................... 37 
2.4. Alendronate Treatment Scenarios ................................................................ 37 
2.5. Model Implementation................................................................................... 38 
3. Results................................................................................................................................... 40 
3.1. Validation ........................................................................................................ 40 
3.2. Long Term Implant Effects ........................................................................... 48 
3.3. Preoperative Alendronate Effects ................................................................. 53 
3.4. Postoperative THR Alendronate Treatment Effects ................................... 55 
3.5. Postoperative ASR Alendronate Treatment Effects.................................... 64 
4. Discussion ............................................................................................................................. 73 
Bibliography................................................................................................................................. 86 
Appendix A User Subroutine ................................................................................................. 91 
Appendix B Extracting Results............................................................................................ 101 
Appendix C Extracting File.................................................................................................. 103 
Appendix D ISV File ............................................................................................................. 107 
Appendix E One Year Porosity Pictures............................................................................. 108 
Appendix F Six Year Porosity Pictures .............................................................................. 110 
Appendix G Six Year Strain Pictures .................................................................................. 112 
 
 
viii 
 
List of Tables 
Table 2-1 shows the different treatment scenarios for preoperative and 
postoperative models.  Treatment scenarios were used for both total hip 
and surface hip replacements.  The main scenarios being compared are 
the postoperative results with a year of treatment for each preoperative 
model treatment....................................................................................... 38 
Table 3-1 shows the preoperative end state porosity change for the total hip 
replacement between no Alendronate treatment and one year of 
Alendronate treatment. ............................................................................ 54 
Table 3-2 shows the preoperative end state porosity change for the articular 
surface replacement between no Alendronate treatment and one year 
Alendronate treatment. ............................................................................ 54 
 
 
ix 
 
List of Figures 
Figure 1-1 shows important features of a typical long bone [12].......................... 4 
Figure 1-2 shows the coupling action of both osteoclasts and osteoblasts 
which make up a BMU [13]. ....................................................................... 6 
Figure 1-3 shows scanning electron micrographs to show the structure of 
L3 vertebra in a 31 year old woman (top) and in a 70 year old 
woman (bottom) [15]. ................................................................................. 7 
Figure 1-4 shows the common bisphosphonate chemical backbone................... 9 
Figure 1-5 shows the chemical formula for Alendronate.................................... 10 
Figure 1-6 shows a radiograph of a patient with hip osteoarthritis. 
http://chicopmr.org/pain/images/hip-xray-osteoarthritis.jpg...................... 12 
Figure 1-7 shows the removed parts of the femur to incorporate a total hip 
replacement [24]. ..................................................................................... 13 
Figure 1-8 shows the Biomet Taperloc stem (left) and Depuy ASR femoral 
component (right) that were used in this study.  Radiographs of an 
implanted hip resurfacing component (top right) and an 
uncemented, tapered stem (bottom right).  Acetabulum components 
can be seen in both radiograph images [34]. ........................................... 16 
Figure 1-9 shows the resurfaced femur (top) with an ASR implant 
(bottom) [24]. ........................................................................................... 17 
Figure 1-10 shows a schematic representation of the adaptive remodeling 
program integrated with finite element method (FEM) code.  The 
feed-back control variable is the difference between the actual 
x 
 
strain energy density (SED), the apparent strain energy density U, 
and homeostatic SED, Un. ....................................................................... 19 
Figure 1-11 shows predicted bone loss around varying stem sizes using 
the strain adaptive algorithm created by Huiskes et al. [37]..................... 20 
Figure 1-12 shows a block diagram representation of bone remodeling 
with multiple feedback loops created by Beaupre et al. driven by 
local, not global signals [40]..................................................................... 22 
Figure 1-13 shows a schematic representation of the bone remodeling 
algorithm developed by Hazelwood et al.  Remodeling is activated 
by disuse and damage and the porosity is determined from the 
activation frequency history [45]. ............................................................. 24 
Figure 1-14 shows that the rate of bone loss after total knee arthroplasty 
below the tibial tray is slower when bisphosphonate effects are 
simulated than without treatment [48]. ..................................................... 28 
Figure 1-15 shows anterior (a) and posterior (b) views of hip joint contact 
and muscle force magnitudes applied to the model as a percentage 
of body weight (BW = 836 N) for three separate load cases: I. heel-
strike phase of walking; II. toe-off phase of walking; III. stair 
climbing. Force application points represent the approximate 
centers of distributed loads [34]. .............................................................. 31 
Figure 1-16 shows the seven sections around the femoral component for 
evaluation [25]. ........................................................................................ 33 
xi 
 
Figure 1-17 shows the percentage change in BAF (bone area fraction, 
equivalent to BVF assuming normal stereologic conditions [58]) 
versus postoperative time for the seven Gruen zones in the total hip 
replacement [34]. ..................................................................................... 34 
Figure 1-18 shows the percentage change in BAF (bone area fraction, 
equivalent to BVF assuming normal stereologic conditions [58]) 
versus postoperative time for the seven Gruen zones in the 
articular surface replacement [34]............................................................ 35 
Figure 3-1 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the total hip replacement validation 
run.  The reference BVF baseline is taken from the day of surgery. ........ 40 
Figure 3-2 shows the postoperative damage in the seven Gruen zones for 
the total hip replacement validation run. .................................................. 41 
Figure 3-3 shows the postoperative activation frequency in the seven 
Gruen zones for the total hip replacement validation run......................... 41 
Figure 3-4 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the articular surface replacement 
validation run.  The reference BVF baseline is taken from the day of 
surgery..................................................................................................... 43 
Figure 3-5 shows a comparison between BMD change results obtained 
clinically by Nishioka et al. [61] and our experimental data one year 
postoperatively for a THR.  There were no apparent differences in 
any GZ. .................................................................................................... 44 
xii 
 
Figure 3-6 shows a comparison between BMD results obtained clinically 
by Nakamura et al. [62] and our experimental data one year 
postoperatively for a THR.  There were statistical similarities in GZ 
3, GZ 4, and GZ 5 and significant differences in GZ 1 (p-value = 
0.037), GZ 2 (p-value = 0.010), GZ 6 (p-value = 0.018) and GZ 7 
(p-value = 0.003)...................................................................................... 45 
Figure 3-7 shows a comparison between BMD change results obtained 
clinically by Arabmotlagh et al. [63] and our experimental data one 
year postoperatively for a THR. There were no significant 
differences. .............................................................................................. 46 
Figure 3-8 shows a comparison between BMD results obtained clinically 
by Nakamura et al. [62] and our experimental data two years 
postoperatively for a THR.  There were statistical similarities in GZ 
1, GZ 3, GZ 4, and GZ 5 and significant differences in GZ 2 (p-
value = 0.027), GZ 6 (p-value = 0.028), and GZ 7 (p-value = 0.039). ...... 47 
Figure 3-9 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the total hip replacement six years 
postoperatively.  The reference BVF baseline is taken from the day 
of surgery................................................................................................. 48 
Figure 3-10 shows the postoperative damage change in the seven 
different Gruen zones for the total hip replacement six years 
postoperatively......................................................................................... 49 
xiii 
 
Figure 3-11 shows the activation frequency in the seven different Gruen 
zones for the total hip replacement six years postoperatively.................. 50 
Figure 3-12 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the articular surface replacement 
six years postoperatively.  The reference BVF baseline is taken 
from the day of surgery. ........................................................................... 51 
Figure 3-13 shows the postoperative damage change in the seven 
different Gruen zones for the articular surface replacement six 
years postoperatively. .............................................................................. 52 
Figure 3-14 shows the activation frequency in the seven different Gruen 
zones for the articular surface replacement six years 
postoperatively......................................................................................... 53 
Figure 3-15 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the total hip replacement six years 
postoperatively with continuous Alendronate treatment. The 
reference BVF baseline is taken from the day of surgery. ....................... 55 
Figure 3-16 shows the postoperative damage change in the seven 
different Gruen zones for the total hip replacement six years 
postoperatively with continuous Alendronate treatment........................... 56 
Figure 3-17 shows the activation frequency in the seven different Gruen 
zones for the total hip replacement six years postoperatively with 
continuous Alendronate treatment. .......................................................... 57 
xiv 
 
Figure 3-18 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the total hip replacement six years 
postoperatively with one year postoperative Alendronate treatment.  
The reference BVF baseline is taken from the day of surgery. ................ 58 
Figure 3-19 shows the postoperative damage change in the seven 
different Gruen zones for the total hip replacement six years 
postoperatively with one year postoperative Alendronate treatment........ 59 
Figure 3-20 shows the activation frequency in the seven different Gruen 
zones for the total hip replacement six years postoperatively with 
one year postoperative Alendronate treatment. ....................................... 60 
Figure 3-21 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the total hip replacement six years 
postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative.  The reference 
BVF baseline is taken from the day of surgery without preoperative 
treatment to visually compare the differences at postoperative time 
0 with pretreatment. ................................................................................. 61 
Figure 3-22 shows the postoperative damage change in the seven 
different Gruen zones for the total hip replacement six years 
postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative..................................... 62 
Figure 3-23 shows the activation frequency in the seven different Gruen 
zones for the total hip replacement six years postoperatively 
xv 
 
starting Alendronate treatment one year preoperative and ending 
one year postoperative. ........................................................................... 63 
Figure 3-24 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the articular surface replacement 
six years postoperatively with continuous Alendronate treatment.  
The reference BVF baseline is taken from the day of surgery. ................ 64 
Figure 3-25 shows the postoperative damage change in the seven 
different Gruen zones for the articular surface replacement six 
years postoperatively with continuous Alendronate treatment. ................ 65 
Figure 3-26 shows the activation frequency in the seven different Gruen 
zones for the articular surface replacement six years 
postoperatively with continuous Alendronate treatment........................... 66 
Figure 3-27 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the articular surface replacement 
six years postoperatively with one year postoperative Alendronate 
treatment.  The reference BVF baseline is taken from the day of 
surgery..................................................................................................... 67 
Figure 3-28 shows the postoperative damage change in the seven 
different Gruen zones for the articular surface replacement six 
years postoperatively with one year postoperative Alendronate 
treatment.................................................................................................. 68 
xvi 
 
Figure 3-29 shows the activation frequency in the seven different Gruen 
zones for the articular surface replacement six years 
postoperatively with one year postoperative Alendronate treatment........ 69 
Figure 3-30 shows the postoperative bone volume fraction changes in the 
seven different Gruen zones for the articular surface replacement 
six years postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative.  The reference 
BVF baseline is taken from the day of surgery without preoperative 
treatment to visually compare the differences at postoperative time 
0 with pretreatment. ................................................................................. 70 
Figure 3-31 shows the postoperative damage change in the seven 
different Gruen zones for the articular surface replacement six 
years postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative..................................... 71 
Figure 3-32 shows the activation frequency in the seven different Gruen 
zones for the articular surface replacement six years 
postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative..................................... 72 
Figure 4-1 shows a comparison between results obtained clinically by 
Arabmotlagh et al. [63] and our experimental data six years 
postoperatively for a THR with no Alendronate treatment.  
Statistical similarities were found  in GZ 1, GZ 2, GZ 6, and GZ 7 
xvii 
 
and significant differences were seen in GZ 3 (p-value = 0.035), GZ 
4 (p-value = 0.012), and GZ 5 (p-value = 0.001)...................................... 74 
Figure 4-2 shows a comparison between results obtained clinically by 
Arabmotlagh et al. [63] and our experimental data one year 
postoperatively for a THR with one year postoperative Alendronate 
treatment.  All regions were statistically similar except one 
significant difference seen in GZ 7     (p-value = 0.004)........................... 75 
Figure 4-3 shows a comparison between results obtained clinically by 
Arabmotlagh et al. [63] and our experimental data six years 
postoperatively for a THR with one year postoperative Alendronate 
treatment.................................................................................................. 76 
Figure 4-4 shows a comparison between results obtained clinically by 
Nishioka et al. [61] and our model data one year postoperatively for 
a THR with one year postoperative Alendronate treatment. .................... 77 
Figure 4-5 shows the bone volume fraction (BVF) change comparisons 
after six years for the major treatment scenarios.  The reference 
BVF baseline is taken from the day of surgery without preoperative 
treatment.................................................................................................. 79 
Figure 4-6 shows the damage for the major treatment scenarios after six 
years. ....................................................................................................... 80 
Figure 4-7 shows the differences in strain adjacent to the ASR rim for the 
different treatment scenarios. .................................................................. 81 
xviii 
 
Figure 4-8 shows the differences in damage adjacent to the ASR rim for 
the different treatment scenarios. ............................................................ 82 
Figure 4-9 compares the BVF percentage adjacent to the ASR rim for the 
different treatment scenarios. .................................................................. 83 
1 
 
1. Introduction 
1.1. Purpose 
A primary concern following total hip arthroplasty is the bone loss in the 
proximal femur [1, 2].  Part of the bone loss is due to stress shielding, where the 
implant takes up a majority of the load applied and transfers it to distal bone, 
creating lower than normal strains on the surrounding bone in the proximal 
aspect.  This bone experiencing lower strain remodels, and decreases the bone 
density for that area increasing the periprosthetic fracture risk and contributing to 
implant loosening [3-5].  This decrease of bone density means less bone stock 
and other options for revision surgery [6].  
Newer uncemented, tapered, titanium stems have shown less bone loss 
over long-term than similar uncemented straight stems [7, 8].  In addition, metal-
on-metal hip resurfacing retains bone stock in the proximal aspect of the femur, 
making it easier to convert to a total hip arthroplasty in revision surgery [9].  This 
is especially important for younger patients with hip osteoarthritis who may need 
several revision surgeries.  Resurfacing arthroplasty is also believed to maintain 
a more natural loading state in the proximal femur.  Recently a group of drugs 
called bisphosphonates have been administered in conjunction with hip 
arthroplasty [10, 11].  Normally used to help prevent bone mineral density loss in 
osteoporosis, bisphosphonates are being used in an attempt to prevent the bone 
loss in the proximal aspect of the femur after hip arthroplasty. 
Computer models that accurately simulate bone remodeling could be 
useful in comparing bone loss following arthroplasty surgeries with 
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bisphosphonate treatment because it’s not always possible to accurately 
measure bone mass density changes clinically.  Existing computer models don’t 
incorporate the underlying biological process of a basic multicellular unit that is 
responsible for bone’s adaptation in response to environmental loading changes 
while looking at the long term bisphosphonate effects.  Existing models also do 
not look into modeling the effects with the use of a surface replacement 
arthroplasty. 
The goal of this project is to integrate bisphosphonate drug treatment into 
a computer model with a bone remodeling algorithm based on the biological 
remodeling process to explore the problem of bone loss following hip 
arthroplasty.  The objectives of this study are to: (1) validate the implementation 
of a previously developed computer model into the current study, (2) implement 
bisphosphonate code into the model, (3) perform and validate long term 
computer simulations to study the mechanisms of bone loss in the proximal 
aspect of the femur for an uncemented tapered stem and a resurfacing 
component under the effects of Alendronate, and (4) evaluate different 
Alendronate treatment scenarios. 
1.2. Bone Structure 
Bone is a dynamic tissue made of collagen, water, hydroxyapatite mineral, 
proteoglycans, and noncollagenous proteins that constantly adjusts to its 
mechanical and physical environment through changes in the microscopic 
architecture and composition [12].  The nonmineralized space in bone contains 
marrow which is a tissue composed of nerves, blood vessels, and other cells.  
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The remaining bone is mineralized and split into two different types determined 
by porosity.  Most bone tissue is either very low porosity or very high porosity.  
The low porosity bone is known as compact bone while the high porosity is 
known as trabecular bone. 
Compact bone forms the cortex for long bones and has a porosity of 5-
10%.  The pores are categorized as either Haversian canals, Volkmann’s canals 
or resorption cavities.  Haversian canals align with the long axis of bone and 
contain the nerves and capillaries.  Volkmann’s canals also contain capillaries, 
and are transverse canals which connect Haversian canals to each other and to 
the outside of bone.  Resorption cavities are the spaces temporarily made by 
osteoclasts during bone remodeling. 
Trabecular bone is normally found at the end of long bones as well as flat 
bones and cuboidal bones and has a porosity of 75-95%.  The pores are filled 
with marrow and the bone matrix forms struts called trabeculae that often seem 
randomly arranged.  Important features of both types of bone can be seen in 
Figure 1-1. 
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Figure 1-1 shows important features of a typical long bone [12]. 
Both types of bone contain two major bone tissue types.  Lamellar bone is 
highly organized and slow forming bone, consisting of layers called lamellae 
which create a matrix of collagen fibers and minerals.  This calcified matrix 
surrounds the Haversian canals in concentric rings which is also called an 
osteon.  Woven bone is poorly organized and quick forming bone where the 
matrix of collagen fibers and minerals is more randomized.  
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1.3. Bone Remodeling 
Within the cortex of bone, basic multicellular units (BMUs) initiate osteonal 
bone remodeling.  BMUs are the coupling of osteoclasts and osteoblasts working 
in teams with a central Haversian canal providing the pathway for capillaries to 
supply needed nutrients which can be seen in Figure 1-2.  BMUs are activated 
by a stimulus such as damage or disuse.   Osteoclasts are multinucleated cells 
formed from monocytes that resorb bone.  The osteoclasts demineralize bone 
with acid and dissolve collagen with enzymes [12].  Normally it takes about three 
weeks to resorb the bone perpendicular to the path of the BMU. Osteoblasts are 
mononuclear cuboidal cells that differentiate from mesenchymal cells. 
Osteoblasts produce the organic portion of the bone matrix [12] and refilling the 
resorption space takes about three months but may take up to six months to 
completely mineralize.  During the remodeling process, osteoblasts can be 
buried inside cavities, called lacunae, in the newly formed bone and can become 
osteocytes.  Osteocytes communicate to each other and other osteoblasts 
through tunnels called canaliculi. The whole remodeling process maintains 
existing bone or changes the porosity, and can realign the trabeculae of 
trabecular bone. 
6 
 
 
Figure 1-2 shows the coupling action of both osteoclasts and osteoblasts which make up a BMU 
[13]. 
1.4. Osteoporosis 
Osteoporosis is defined as a disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue leading to enhanced bone fragility 
and a consequent increase in fracture risk [14].  Most notably, the vertebra, hip 
and wrist bones become porous and weak, making them susceptible to fracture 
after minimal forces or pressure.  The underlying mechanism is an imbalance 
between an increased resorption of bone and decreased formation of bone, and 
normally presents itself in low trauma fracture, backache, height loss, spinal 
deformity, or in radiological bone mineral density [15].  An example of bone 
microarchitectural deterioration can be seen in Figure 1-3. 
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Figure 1-3 shows scanning electron micrographs to show the structure of L3 vertebra in 
a 31 year old woman (top) and in a 70 year old woman (bottom) [15]. 
Some risk factors of osteoporosis include sex and race, age, early 
menopause, family history of osteoporosis, lack of estrogen, poor calcium intake, 
smoking, heavy alcohol or caffeine consumption, and a lack of exercise [16-18].  
Women are at most risk due to a lower peak of bone mass, an increased bone 
loss at menopause, and a higher life expectancy [15].   The risk for a fracture 
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increases dramatically with age, decreasing the lifespan and increasing the 
mortality rate [15].   
The treatment of osteoporosis is based upon bone mineral density in the 
spine and proximal femur using a dual energy x-ray absorptiometry (DXA).  To 
be diagnosed with osteoporosis, a bone mineral density of 2.5 or more standard 
deviations away from the normal peak bone mass must be observed.  DXA is 
used primarily because it is fairly inexpensive, involves low radiation exposure, 
and can measure bone density accurately in areas where fractures are the most 
common [17]. 
Ideally, people want to prevent osteoporosis by optimizing their skeletal 
bone mass throughout life, and to keep bone mineral density levels as close to 
peak levels as possible.  Doing this can be accomplished by taking actions aimed 
at the risk factors outlined above.  Therapeutic options now exist for those who 
are diagnosed with osteoporosis.  Some of these options include 
bisphosphonates, raloxifene and hormone replacement therapy, strontium 
ranelate, and parathyroid hormone peptides. 
1.5. Bisphosphonates 
Bisphosphonates are related to pyrophosphate in which the oxygen bridge 
is replaced by a carbon with various side chains.  They were developed and used 
in the treatment of bone disease after being discovered that they effectively 
control calcium phosphate formation and dissolution as well as mineralization 
and bone resorption in vivo.  Bisphosphonates bind strongly to the bone mineral, 
hydroxyapatite, which explains the mode of action for the drug.  Deposits form 
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where bone mineral is exposed to surrounding fluids, especially areas of bone 
formation and resorption.  The release of bisphosphonates in the body is 
primarily when the bone is being resorbed again.  Otherwise, due to the chemical 
backbone of bisphosphonates (P-C-P group) being enzymatically resistant seen 
in Figure 1-4, the body is unable to metabolize the compound and they are 
excreted by the kidneys without alteration.  The charge and the size of the 
bisphosphonate limits the penetration through different cellular membranes [19]. 
 
Figure 1-4 shows the common bisphosphonate chemical backbone. 
Effects of bisphosphonates can be separated into several categories.  At 
the tissue level, bisphosphonates reduce bone turnover by decreasing both bone 
resorption and bone formation.  Since there is a negative balance at each BMU, 
a decrease in the turnover leads to a decrease in bone loss.  There isn’t 
evidence of reduction of osteoblast activity at each site however, so the amount 
of bone formed at each BMU is not decreased, but increased.  Also, after a 
decreased turnover, newly formed bone has more time to complete 
mineralization since there’s less chance of it being remodeled.  Both these create 
an increase in the amount of bone in humans.  At the cellular level, the final 
target of bisphosphonates is the osteoclast.  Different ways of reducing 
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resorption by the osteoclast include inhibition of recruitment to the bone surface, 
inhibition of activity at the bone surface, shortening of the lifespan, or alteration of 
the bone mineral in ways which reduce the rate of dissolution.  At the molecular 
level, it’s possible bisphosphonate action on a cell surface or bisphosphonate 
uptake by the cell interacts with an enzyme or other molecule, affecting cellular 
metabolism [19]. 
The potency of bisphosphonates depends on the side chains connected to 
the backbone, and typically are separated into either a nitrogenous groups or a 
non-nitrogenous group.  Those with a nitrogen side group are considered to be 
the most potent.  One example of a potent bisphosphonate is Alendronate 
(commercially known as Fosamax).  Alendronate (C4H12NO7P2Na·3H2O) is 
considered a first line option and normally taken orally when fasting, however it 
can be taken intravenously as well [15].  Some adverse effects include upper 
gastrointestinal intolerance [20] as well as auditory, visual, and olfactory 
hallucinations [21].  The chemical structure of Alendronate can be visualized in 
Figure 1-5. 
 
Figure 1-5 shows the chemical formula for Alendronate 
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1.6. Osteoarthritis 
Osteoarthritis is the most common type of arthritis, estimated in12.1% of 
the adult population and about 20% of people above the age of 65 will be at high 
risk in the year 2030 [22].  Before 1986 osteoarthritis was regarded as a 
degenerative disease involving articular cartilage and subchondral bone but it 
has become viewed as a syndrome with many complex etiologies [23].  
Osteoarthritis is currently characterized physiologically by focal areas of damage 
to the articular cartilage, changes in the subchondral bone, as well as synovitis 
and capsular thickening [23].  Radiographs help to see the joint space, as seen in 
Figure 1-6, and changes of subchondral bone but people with severe 
radiographic change can still be symptom free.  Symptoms normally include pain, 
stiffness after activity, popping, and swelling of the joint.  Women are at higher 
risk than men and the risk increases with age as well.  Therapies for 
osteoarthritis include lifestyle modification and pharmacological treatment before 
the long term solution of a joint surgery [22, 23]. 
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Figure 1-6 shows a radiograph of a patient with hip osteoarthritis. 
http://chicopmr.org/pain/images/hip-xray-osteoarthritis.jpg 
1.7. Hip Arthroplasty 
Hip arthroplasty is the artificial replacement of the joint which connects the 
pelvis to the femur.  In order to recreate the ball and socket joint, both the femur 
and acetabulum have parts surgically removed.  On the femur, the head and part 
of the neck is removed in order to fit a metal stem into the medullary canal which 
can be seen in Figure 1-7.   
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Figure 1-7 shows the removed parts of the femur to incorporate a total hip replacement 
[24]. 
On top of the stem sits a metal ball, normally composed of cobalt 
chromium, to replicate the femur head.  A small part of the acetabulum is 
removed in order to fit a metal cup lined with ultra-high molecular weight 
polyethylene (UHMWPE) for the replicated femur head to fit into.  This cup can 
be seen in Figure 1-8. 
When early metallic implants made of cobalt chrome started to be used, 
femur designs used bone cement made of polymethylmethacrylate (PMMA) to 
help secure the fixation.  While the cement did initially aid in fixation of the 
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femoral implant, the interfaces of the cement with both bone and implant failed, 
leading to high loosening rates [25] causing further damage to the bone.  
Due to the high loosening rates, uncemented implants were used more.  
Using a larger diameter stem with a press fit into the bone created a strong 
fixation and solved the problem with the bone cement.  Unfortunately, the new 
design structure of the stem with increased size and high stiffness caused stress 
shielding.  To address the high stiffness, more flexible titanium stems with a 
proximally porous coating to allow for bone to grow into the stem were used and 
determined to lead to less bone resorption compared to the cobalt chrome with 
extensive porous coating [26, 27].  The stem used in this study, seen in Figure 1-
8, is an uncemented, tapered, titanium stem which has shown less bone loss 
long term than similar uncemented straight stems. 
Even with improvements in fixation and in the bearing of surfaces, total hip 
arthroplasty did not have encouraging results for all patients.  Articular surface 
replacement became popular due to a larger demand from younger, more active 
patients [28] for the preservation of bone stock as well as less stress shielding in 
the proximal femur because of the possible need for revision operations [29]. 
Resurfacing the femur involves removing part of the femur head and covering it 
with a hemispherical shell with a short stem as seen in Figure 1-9.  Early 
material for articular surface replacement by Smith-Petersen tried using glass, 
due to its inertness, and viscaloid, which ended up causing too much foreign 
body response [30] before a cobalt chrome alloy was introduced later.  
Resurfacing in the 1970’s started using a metal stem with a polyethylene 
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acetabular cup but long term studies showed high failure rates [29] due to 
loosening which caused wear debris, initiating a foreign body response [31].  
Within the past 10 years, resurfacing has become even more popular due to 
better manufacturing techniques [32].  The new components use metal femoral 
and acetabular parts, reducing the wear and failure rates  [32], however there are 
some concerns about the implantation procedure and fracture risk of which the 
mechanism is unknown [33].  It also is not possible to measure bone mineral 
density changes within the femoral head and certain regions of the femoral neck 
using DXA scans.  These metal on metal implants have demonstrated short term 
success [29] but much about the wear debris and long term success are still 
unknown. 
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Figure 1-8 shows the Biomet Taperloc stem (left) and Depuy ASR femoral component 
(right) that were used in this study.  Radiographs of an implanted hip resurfacing 
component (top right) and an uncemented, tapered stem (bottom right).  Acetabulum 
components can be seen in both radiograph images [34]. 
17 
 
 
Figure 1-9 shows the resurfaced femur (top) with an ASR implant (bottom) [24]. 
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Recently, bisphosphonates like Alendronate have been used with hip 
replacements to help against stress shielding.  The bisphosphonates are used in 
order to preserve the bone mass of the femur, however their anti-resorptive 
action may lead to increases in fatigue microdamage. 
1.8. Previous Remodeling Simulations 
Many algorithms to explain the architecture and properties of bone have 
been developed based on the observations by Wolff which resulted in his 
hypothesis known today as “Wolff’s Law” [35].  Wolff states that bone has the 
adaptive property to change its architectural shape and external form in response 
to mechanical stimuli, limited to certain mathematical rules.  Since modeling rates 
slow down significantly more compared to remodeling rates when reaching 
skeletal maturity [12], most algorithms focus on predicting bone changes due to 
remodeling.   
Cowin et al. created an algorithm for the adaptive process of bone 
describing it as an elastic material which adapts structurally to an applied loading 
[36].  This model maintains a level of bone strain through either modeling or 
remodeling processes to adjust the density of cortical bone.  Taking this adaptive 
elasticity model further, Huiskes created an algorithm that would model or 
remodel bone in order to maintain a constant level of strain energy density [37].  
A schematic of this algorithm can be seen in Figure 1-10.   
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Figure 1-10 shows a schematic representation of the adaptive remodeling program 
integrated with finite element method (FEM) code.  The feed-back control variable is the 
difference between the actual strain energy density (SED), the apparent strain energy 
density U, and homeostatic SED, Un. 
Implementing this algorithm with a prosthesis used in total hip 
arthroplasty, the effects of stress shielding on bone loss based upon the loaded 
implant was modeled two-dimensionally.  They created a set threshold for 
homeostatic strain energy density, and an increase or decrease outside this 
range results in bone gain or loss, respectively.  The two dimensional model then 
incorporated these effects by modeling straight stem implants of increasing 
diameter subjected to loading in a straight bone shaft.  The model representation 
created was adequate enough to describe the three-dimensional structural 
integrity of the bone.  The study also helped predict the effects of stem rigidity 
and degree of fixation related to stress shielding as can be seen in Figure 1-11. 
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Figure 1-11 shows predicted bone loss around varying stem sizes using the strain 
adaptive algorithm created by Huiskes et al. [37] 
Continuing with this work, Huiskes et al. [38] looked at a two-dimensional 
model to describe the post-loosening mechanical behavior of surface 
replacements.  The cup was modeled with linear beam elements in the frontal 
plane and spanning beam elements in the medial and lateral sides that 
corresponded to a solid model showing equivalence. A bi-linear stress-strain 
behavior, low elastic modulus, and gap elements were used to model the fibrous 
tissue.  The results indicate that high failure rates are correlated indirectly with 
the implant design to implant loosening and the propagation of bone resorption 
and fibrous tissue formation.  This suggested that the ability of these implants to 
obtain a stable post-loosening configuration is an important design criterion for 
the long-term survival. 
 
21 
 
Furthering the algorithm use, Huiskes et al. [39] looked at the relationship 
between stress shielding and bone resorption around total hip stems and the 
effects of flexible materials in a three-dimensional model.  They found flexible 
stems reduce stress shielding and bone resorption but they increase the proximal 
surface stresses.  The findings also supported the hypothesis that resorption 
processes are an effect of bone adaptation to stress shielding and individual 
variations in bone reactivity and mechanical bone quality may account for the 
individual differences found in experiments. 
Another algorithm created by Beaupre et al. [40] determined the net 
resorption and formation by taking the difference between the stimulus and the 
tissue attractor state.  The attractor state is the level of daily loading necessary to 
maintain bone at a known density.  They use a time dependent approach for 
modeling and remodeling, taking into account the amount of bone surface area 
both osteoclasts and osteoblasts can work.  The model uses local signals which 
don’t necessarily lead toward global optimization.  Each bone site optimizes its 
own environment instead of towards the structure as a whole.  This means during 
normal aging, local changes made by modeling and remodeling never stop, 
indicating the model never converges just like actual bone.  However, the rate of 
change will diminish as each site reaches the attractor state. A diagram of their 
remodeling code can be seen in Figure 1-12. 
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Figure 1-12 shows a block diagram representation of bone remodeling with multiple 
feedback loops created by Beaupre et al. driven by local, not global signals [40]. 
A three-dimensional, iterative model by Van Rietbergen et al. [41] used 
the site formulation theory as well.  This theory assumes the treated bone with an 
implant attempts to normalize its stress-strain patterns to the same value as the 
untreated bone [37].  They also incorporate Martin’s theory [42] that says bone 
apposition and resorption can occur only at free bone surfaces.  Bone mass is 
regulated by elastic strain energy per unit mass, and when the difference 
between the treated bone and untreated bone reaches a certain threshold, no 
remodeling takes place and the model converges.  More recently, Gupta et al. 
[43] uses this adaptive bone remodeling theory to assess the short term risk of 
femoral neck fracture (1-2 years) and long term risk of failure of fixation (5 years) 
of a cemented resurfacing femoral head.  Results showed strain shielding in the 
femoral head with a 50-90% reduction in bone density in the superior femoral 
head region and elevated strains of 0.50 – 0.80% generated in the superior 
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femoral neck.  These high strains only occurred in a small fraction of bone 
indicating a low risk of fracture post-surgically and the strains were considerably 
reduced after bone remodeling leading to an even smaller chance of fracture. 
Peter et al. [44] takes a remodeling algorithm and adds in bisphosphonate 
treatment.  The model developed takes into account bone inhomogeneity and 
bone transverse isotropic symmetry by using relative density and an anisotropy 
tensor.  For this short term simulation, the bone density is linked to the 
mechanical stimulus in a linear relation and the tensor is kept constant. To 
simulate the drug, the resorption parameters are affected with the formation 
parameters kept constant.  
1.9. Remodeling Algorithm 
The remodeling algorithm used in this study was developed by Hazelwood 
et al. [45] and models the activity of basic multicellular units (BMUs) responsible 
for resorbing and depositing bone through activation by both disuse and fatigue 
microdamage.  A schematic of this algorithm can be seen in Figure 1-13. 
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Figure 1-13 shows a schematic representation of the bone remodeling algorithm 
developed by Hazelwood et al.  Remodeling is activated by disuse and damage and the 
porosity is determined from the activation frequency history [45]. 
The model can adapt its porosity over time in local areas of disuse or 
damage throughout the entire bone since it simulates BMU behavior.  In the 
remodeling code, the rate change in porosity ( ) is the difference between the 
resorbing and refilling rates. 
(1)  
 The resorption rate ( ) is the product of the resorption rate per BMU 
(  and the number of resorbing BMUs/area ( ).  Similarly, the refilling rate 
( ) is the product of the refilling rate per BMU ( ) and the number of refilling 
BMUs/area ( ).  The number of BMUs resorbing and refilling varies as a 
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function of BMU activation frequency.  The resorption ( ) and refilling 
( ) rates are calculated by the average area resorbed or refilled per 
BMU ( ) divided by the resorption or refilling time period ( respectively). 
Net bone resorption occurs during disuse and initially during microdamage 
removal.  Activation frequency ( ) is defined as the sum of the activation 
frequency due to disuse ( ) and the activation frequency due to damage 
( ), multiplied by the specific surface area ( ).  The specific surface 
area is the free internal surface area per unit volume that’s available for 
remodeling and uses normalized values between 0 and 1. 
(2)  
 Damage ( ) is defined as a crack length per area of bone.  The rate of 
fatigue damage is described as the difference in fatigue damage formation ( ) 
and removal ( ) rates. 
(3)  
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The fatigue damage formation rate ( ) is assumed to be proportional to the 
product of the strain ( ) raised to a power ( ) and the loading rate ( ) summed 
over  loading conditions [46]. 
(4)  
 In this equation,  represents the summation term and is known as the 
mechanical stimulus and  is the damage rate coefficient.  The exponent  
balances the relative importance between strain magnitude and the number of 
loading cycles and in the case of this study, a value of 4 is used based on 
previous research [40, 45, 46]. 
 If we assume damage and BMUs are random throughout the bone, then 
the fatigue damage removal rate ( ) would equal the product of damage ( ) 
and the area fraction resorbed per day ( ) where  is the cross sectional area 
of a BMU.  However in the model, it is assumed damage actually initiates BMU 
activation which means the damage removal rate would be greater than random 
remodeling.  Since the rate would be greater, a specificity factor ( ) was 
included. 
(5)  
27 
 
 Disuse for the model is defined as a level of mechanical stimulus ( ) 
below the equilibrium stimulus ( ).  To model the effects of disuse, BMU 
activation frequency is increased when below a given stimulus threshold and the 
refilling rate is reduced as well [47].  The relationship between activation 
frequency due to disuse and activation frequency due to damage are assumed 
sigmoidal which enables activation frequency calculation.  Once calculated, the 
number of resorbing and refilling BMUs can be determined, followed by the rate 
of change in porosity (Eq. 1). 
1.10. Bisphosphonate Algorithm 
The bisphosphonate effects for this study are modeled according to code 
implemented by Nyman et al [48, 49].  This treatment reduces activation 
frequency [19, 50-52] as well as the resorption cavity size [19, 51-53] to account 
for Alendronate. The potency of suppressing the activation frequency is a 
function of the number of resorbing BMUs. 
(6)   
where Pmax is the maximum suppression coefficient,  is the rate of suppression 
coefficient, and NR is the number of resorbing BMUs.  Both variables reflect the 
dosage and structure of the bisphosphonate.  Nyman incorporated this 
bisphosphonate code into a two-dimensional model for knee arthroplasty to 
investigate the long-term effects to minimize proximal bone loss and found 
bisphosphonate treatment to slow the rate of bone loss by 42% after one year as 
seen in Figure 1-14 [48]. 
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Figure 1-14 shows that the rate of bone loss after total knee arthroplasty below the tibial 
tray is slower when bisphosphonate effects are simulated than without treatment [48]. 
 
1.11. Finite Element Analysis Modeling 
Algorithms can be integrated into finite element models that have a 
variable modulus as a function of bone density because changes in strain drive 
the remodeling process.  Previously, studies have been performed to examine 
postoperative changes in femoral bone density to evaluate effects of different 
muscle groups on the remodeling process as well as changes following hip 
arthroplasty [43, 54, 55].  Deuel improved the current three-dimensional femur 
models by implementing the remodeling algorithm by Hazelwood et al. in order to 
incorporate the biological mechanism of remodeling to study changes in bone 
density following total hip and hip resurfacing arthroplasty procedures. 
The previous simulations using this algorithm were performed with a two-
dimensional model by Hazelwood and Mizumoto [56].  The model was created 
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from a radiograph and used joint reaction and abductor muscle forces which 
originally started in a homogenous bone density distribution.  With the 
remodeling algorithm, the model was allowed to evolve until reaching a steady 
state condition.  Bone loss predictions by the model were consistent with the 
measurements clinically found after surgery. 
Similarly, Nyman et al. [57] incorporated the remodeling algorithm into a 
two-dimensional finite model of the tibia to investigate bone loss following total 
knee arthroplasty (TKA).  The model predicted most bone loss to happen during 
the first six months following surgery which was also consistent with clinical 
findings. 
1.12. Current Model 
The femur model created by Deuel et al. [34] was created from a CT scan, 
using a LightSpeed QXi CT scanner, (GE Healthcare, Milwaukee, WI) of a male 
cadaveric femur with soft tissue removed.  Mimics (Materialise USA, Ann Arbor, 
MI) was used to create the initial two-dimensional surface mesh from the scan 
which was then imported into Patran (MSC Software Corporation, Santa Ana, 
CA) and converted into a three-dimensional mesh using second order tetrahedral 
elements.  A convergence study was then performed using a simplified loading 
scheme of hip joint and abductor forces to compare principle strains and 
displacements and enable an appropriate mesh density selection.  The finite 
element solver Abaqus (Simulia, Providence, Rhode Island) was used for all 
analyses. 
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Two similar meshes of the native femur were created to allow the removal 
of elements for both the resurfacing implant and tapered stem.  For the native 
femur used in the tapered stem model, the finite element mesh consisted of 
45,691 elements and 63,986 nodes and for the resurfacing implant the mesh 
consisted of 29,175 elements and 41,723 nodes.  This original model consisted 
of a solid mesh with elements having homogeneous material properties based on 
experimentally measured values of cortical bone. 
Three load cases during the single stance phase of walking and stair 
climbing were used in the model for hip joint contact and muscle forces.  These 
cases included the loading during heel strike and toe-off phases of normal 
walking and maximum forces during stair climbing.  Normal activity levels of 
patients with normal functioning total hip replacements included 5000 daily 
loading cycles during walking and 20 daily cycles for stair climbing.  Using a body 
weight of 836 N based on the weight of a typical patient undergoing total hip 
arthroplasty surgery, magnitudes and directions of hip joint and abductor muscle 
forces were calculated to determine appropriate joint loading angles during 
walking and stair climbing as can be seen in Figure 1-15.  Only the gluteus 
medius, gluteus minimus, adductor longus, adductor brevis, psoas, vastus 
lateralis, and the vastus medialis muscle groups were used because they have 
previously demonstrated to be the most significant influence on strain distribution 
and remodeling.  The distal region of the femur model was constrained rigidly 
above the femoral condyles. 
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Figure 1-15 shows anterior (a) and posterior (b) views of hip joint contact and muscle 
force magnitudes applied to the model as a percentage of body weight (BW = 836 N) for three 
separate load cases: I. heel-strike phase of walking; II. toe-off phase of walking; III. stair climbing. 
Force application points represent the approximate centers of distributed loads [34]. 
The hip replacement models used are a 49 mm resurfacing femoral 
component (ASR, DePuy, Warsaw, Indiana) and an 11 x 142 mm uncemented, 
titanium, tapered femoral stem with a 32 mm cobalt chrome head (Taperloc, 
Biomet, Warsaw, Indiana).  With the remodeling algorithm, the models evolved 
under loading from its initial homogenous material state until the remodeling 
porosity, damage, and activation frequency reached steady state values.  Data 
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from a comparative experimental study between hip resurfacing versus total hip 
arthroplasty were then used to validate the computational finite element model 
[24].   
After validation, the model simulated reduced loading conditions due to 
pain and loss of function because of hip osteoarthritis.  Hip joint contact and 
muscle force magnitudes were decreased by 6% and the number of loading 
cycles was reduced by 20% as well.  One year of this reduced loading was used 
to describe the preoperative state due to hip osteoarthritis.  Following the 
preoperative state, either the hip resurfacing or tapered stem components were 
introduced to the model.  Reduced loading continued for 3 months 
postoperatively and then returned to normal but with a continued reduction in 
loading cycles by 10% until one year postoperatively.  The remodeling simulation 
was run for a total of 2 years postoperatively and changes in bone density were 
compared between the resurfacing and tapered stem implants using seven 
regions of interest defined by Gruen et al. which can be seen in Figure 1-16 [25]. 
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Figure 1-16 shows the seven sections around the femoral component for evaluation [25]. 
Deuel et al. found a 5% mean loss in bone density across all Gruen zones 
(GZ) over the one year preoperative period.  Implantation of the total hip 
replacement showed bone loss most prominent in region 7 with a 24% loss of 
bone volume fraction (BVF) at two months and remained approximately 25% 
after two years.  Damage levels decreased rapidly during the initial postoperative 
period and activation frequency increased, indicating strain shielding.  Bone 
resorption was also observed in zones 6 and 7 and stabilized at about two years.  
A reduction in BVF of 8% was observed in region 5 and damage levels increased 
over the two years suggesting increased remodeling from damage.  Reductions 
in BVF of 4% or less were observed in all the other zones.  Changes in the BVF 
34 
 
over the two year period for the total hip replacement can be seen in Figure 1-
17. 
 
Figure 1-17 shows the percentage change in BAF (bone area fraction, equivalent to BVF 
assuming normal stereologic conditions [58]) versus postoperative time for the seven 
Gruen zones in the total hip replacement [34]. 
For the resurfacing implant, small amounts of transient bone loss occurred 
in all regions within the first two months and nearly returned to preoperative 
levels after two years.  The maximum loss of BVF in all zones was about 2% or 
less.  Reductions in bone density were most notable in the superolateral and 
inferomedial regions of the femoral head.  The inferior region of the femoral neck 
showed a transient BVF loss with density decreasing rapidly in the first two 
months and then increasing over the next two years, but not returning to 
preoperative levels.  Damage levels were high and still increasing, but at a 
decreased rate in this area.  Changes in the BVF over the two year period for the 
articular surface replacement can be seen in Figure 1-18. 
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Figure 1-18 shows the percentage change in BAF (bone area fraction, equivalent to BVF 
assuming normal stereologic conditions [58]) versus postoperative time for the seven 
Gruen zones in the articular surface replacement [34]. 
Using this model and incorporating the bisphosphonate code can give a 
better understanding of the long term effects of the femur with both hip 
replacement and drug interactions.  The aim of the experiment is to incorporate 
both of these effects into a user subroutine combined with the finite element 
model to compare changes in femoral bone density, activation frequency, and 
damage between types of hip implants as well as drug regimens.  The trends this 
information will show can help physicians decide which type of hip replacement 
to use bisphosphonate drugs with and when to administer the drugs. 
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2. Methods 
2.1. Model Recreation 
For the current study, the first step was to recreate the finite element 
model simulation by Deuel et al. [34].  This model contained a user material 
subroutine (Appendix A) in Abaqus which allowed the model to adapt to different 
loading conditions mimicking how bone changes to its loading environment.  The 
algorithm developed by Hazelwood et al. [45] models BMUs which are 
responsible for the resorption and formation of bone after being activated by both 
disuse and fatigue microdamage.  This allows adaptation of porosity over time in 
localized areas of disuse or damage.  Porosity in the model can be defined as 
the void volume fraction with bone volume fraction (BVF) equal to 1 – porosity.  
Increases in damage and loading may result in increased porosity and decreased 
density, or BVF, during the lag period.  Several small changes were made to the 
existing user material subroutine enabling Abaqus to run properly in our 
laboratory.   
2.2. Model Incorporation and Validation 
The model for this experiment included the implants described previously.  
The initial mesh was created from a CT scan of an intact cadaveric femur and a 
convergence study was performed to select the correct mesh density.  Originally, 
the intact model was allowed to evolve under loading from its initial homogenous 
state until porosity, damage, and activation frequency reached steady state 
values, defined by a change of less than 5% over a period of 30 days.  The 
steady state intact model was validated through clinical experimentation by Deuel 
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et al [34].  The steady state intact model then was subjected to reduced loading 
conditions lasting for one year, which resulted in the preoperative model.  Next, 
either the resurfacing or total hip replacement was introduced to the model, 
resulting in the postoperative model.  Load magnitudes were returned to normal 
after three months, but still with a slight reduction in loading cycles until one year 
after surgery.  After recreating the preoperative and postoperative finite element 
models, we validated our current running simulation through Gruen zone 
comparisons to results obtained by Deuel et al [34] as well as those obtained 
clinically at one and two years. 
2.3. Alendronate Code 
Using the algorithm by Nyman et al. [49] as described previously (section 
1.10), a maximum suppression coefficient (Pmax) of 1.0 and a rate of suppression 
coefficient ( ) of 5 reduces activation frequency by a percentage P.  Adding in a 
reduction in the resorption area by 3/13 observed previously by Chavassieux et 
al [50], the complete Alendronate treatment was simulated, corresponding to 10 
mg of Alendronate daily [48] or 70 mg weekly [59, 60].  Simulations with these 
values give similar results to that observed by dual-energy x-ray absorptiometry 
over 7 years in the spines of postmenopausal women who were treated with 10 
mg of daily Alendronate [59]. 
2.4. Alendronate Treatment Scenarios 
When implementing the Alendronate treatment, we wanted to look at 
differences in treatment times and the results following termination of treatment.  
Each simulation ran for a total of six years postoperatively for either the 
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resurfacing hip or total hip arthroplasty models and was compared to mean data 
from experimental studies.  Six years was chosen in order to compare results 
with Arabmotlagh et al [59] for long term Alendronate effects.  A list of the various 
treatment simulations can be seen in Table 2-1.  These different treatments were 
then compared between each other, between the different types of implants, and 
between the non-treatment scenario by looking at differences in damage, 
activation frequency, and porosity at specific regions (the Gruen zones) of the 
femur.  The main comparisons were between the postoperative models having 
no treatment, one year of treatment, and six years of treatment and between the 
models with one year of postoperative treatment with either no preoperative 
treatment or with a full year of preoperative treatment. 
Table 2-1 shows the different treatment scenarios for preoperative and postoperative 
models.  Treatment scenarios were used for both total hip and surface hip replacements.  
The main scenarios being compared are the postoperative results with a year of 
treatment for each preoperative model treatment. 
Preoperative Model Treatment (1 
year) 
Postoperative Model Treatment (6 years 
total) 
Six years with no Alendronate 
Six years of Alendronate No Alendronate 
First year with Alendronate 
One year of Alendronate First year with Alendronate 
 
2.5. Model Implementation 
Models were run on a Dell Precision 490 (N-series) computer (Dell, Round 
Rock, Texas) with Red Hat Linux (Red Hat, Raleigh, North Carolina) using 
Abaqus version 6.7 (Simulia, Providence, Rhode Island).  In order to run a 
postoperative model, a text file holding all the state variables is created from the 
last step of the preoperative model and is called for in the user material 
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subroutine to initialize the postoperative simulation. The code, created by Deuel 
et al, is shown in Appendix B.  In order to extract results from our models we use 
two files in conjunction.  The executable file reads in an .isv file that contains the 
model file where we want to extract results, the new file name containing the 
results, the starting and stopping steps we want to extract results from, and the 
list of elements in the desired Gruen zone that we want data from.  The 
executable then takes all this information and formats data for activation 
frequency, porosity, and damage.  This file also allows us to determine the step 
interval to extract from.  The extracting executable file can be seen in Appendix 
C, and the .isv file can be seen in Appendix D. 
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3. Results 
3.1. Validation 
The reduced loading conditions representative of preoperative 
changes due to hip osteoarthritis resulted in a 1% mean bone density loss 
over all GZ over one year.  Further loss of femoral bone density resulted after 
implementing the tapered stem into the model.  The most prominent bone 
loss occurred in GZ 7, seen in Figure 3-1, with about a 24% BVF loss within 
two months, and remaining around 25% after two years. 
 
Figure 3-1 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the total hip replacement validation run.  The reference BVF baseline is 
taken from the day of surgery. 
Damage levels for this zone initially decreased rapidly, seen in 
Figure 3-2, while activation frequency increased, seen in Figure 3-3, 
indicating an area of strain shielding. 
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Figure 3-2 shows the postoperative damage in the seven Gruen zones for the total hip 
replacement validation run. 
 
Figure 3-3 shows the postoperative activation frequency in the seven Gruen zones for 
the total hip replacement validation run. 
42 
 
A reduction in BVF of about 8% could also be viewed in GZ 5.  During this 
time period, damage levels in this zone continued to increase suggesting that the 
losses in density weren’t due to stress shielding, but instead due to an increase 
of remodeling from damage removal in this area.  All other reductions in bone 
density were significantly less in other regions, with a loss of 4% or lower in all 
other GZ.  The distal end of the stem had slightly higher losses seen in GZ 3 and 
4. 
After implementing the resurfacing implant into the model a small amount 
of bone loss occurred over all GZ within the first two months following 
implantation, however bone density values nearly returned to preoperative levels 
by the end of the two year period with a maximum BVF loss under 2% for all GZ.  
These changes can be seen in Figure 3-4. 
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Figure 3-4 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the articular surface replacement validation run.  The reference BVF 
baseline is taken from the day of surgery. 
Comparing our results to clinical data, we validated our model at one and 
two year postoperative time.  These studies all used dual energy X-ray 
absorptiometry (DEXA) to measure the small changes in bone mass.  At one 
year, there were no apparent differences in the percent BMD change found when 
comparing our results to Nishioka et al. [61] seen in Figure 3-5.  Visual 
inspections of the standard deviation results obtained by Nishioka et al. were 
used for this determination since the values were not given. 
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Figure 3-5 shows a comparison between BMD change results obtained clinically by 
Nishioka et al. [61] and our experimental data one year postoperatively for a THR.  There 
were no apparent differences in any GZ. 
Comparing to Nakamura et al, [62] after one year there were no significant 
differences in BMD changes after one year postoperatively following THR 
surgery n GZ 3, GZ 4, and GZ 5, but the model overpredicted the BMD changes  
in GZ 1 (p-value = 0.037), GZ 2 (p-value = 0.010), GZ 6 (p-value = 0.018) and 
GZ 7 (p-value = 0.003)  as seen in Figure 3-6. 
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Figure 3-6 shows a comparison between BMD results obtained clinically by Nakamura et al. [62] 
and our experimental data one year postoperatively for a THR.  There were statistical similarities 
in GZ 3, GZ 4, and GZ 5 and significant differences in GZ 1 (p-value = 0.037), GZ 2 (p-value = 
0.010), GZ 6 (p-value = 0.018) and GZ 7 (p-value = 0.003). 
After one year, there were no significant differences in the percent BMD 
change compared to the results of Arabmotlagh et al. [63] as seen in Figure 3-7. 
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Figure 3-7 shows a comparison between BMD change results obtained clinically by 
Arabmotlagh et al. [63] and our experimental data one year postoperatively for a THR. 
There were no significant differences. 
Looking at results from Nakamura et al. [62] once again after two years 
postoperative, there were no significant differences in BMD changes after two 
years postoperatively following THR surgery in GZ 1, GZ 3, GZ 4, and GZ 5, but 
the model again overpredicted the BMD changes  found in GZ 2 (p-value = 
0.027), GZ 6 (p-value = 0.028), and GZ 7 (p-value = 0.039) which can be seen in 
Figure 3-8. 
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Figure 3-8 shows a comparison between BMD results obtained clinically by Nakamura et 
al. [62] and our experimental data two years postoperatively for a THR.  There were 
statistical similarities in GZ 1, GZ 3, GZ 4, and GZ 5 and significant differences in GZ 2 
(p-value = 0.027), GZ 6 (p-value = 0.028), and GZ 7 (p-value = 0.039). 
Comparisons of the model results with those from literature confirm the 
validity of the model used in the current study.  While there were significant 
differences in some regions between our experimental results and those of 
Nakamura et al, [62] the clinical data is almost fifteen years old.  The model 
results were statistically similar to the results from the most current research 
groups.  Looking at the values from these clinical experiments, the success with 
the newer clinical studies shows more bone being retained which could be 
attributed to the advancement of hip prosthesis in the last fifteen years.   With 
current clinical results being similar to our computer simulated model, this 
allowed us to evaluate the long term effects of joint replacement as well as the 
effects with Alendronate treatment. 
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3.2. Long Term Implant Effects 
Both total hip and articular surface replacement models were run 
postoperatively for a total of 6 years.  For the total hip replacement, reductions in 
BVF continued until about four years postoperatively.  After four years, GZ 7 
maintained about a 30% BVF change, seen in Figure 3-9, due to stress 
shielding.  Reductions in BVF continued in GZ 5 for three years and then 
maintained a BVF loss of about 13%.  
 
Figure 3-9 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the total hip replacement six years postoperatively.  The reference BVF 
baseline is taken from the day of surgery. 
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While damage levels off for GZ 2-6, it continues to rise for GZ 1 and 7 
throughout the six year period, seen in Figure 3-10. 
 
Figure 3-10 shows the postoperative damage change in the seven different Gruen zones 
for the total hip replacement six years postoperatively. 
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Activation frequency leveled off for all GZ at three to four years 
postoperatively as seen in Figure 3-11.  The sharper increases for activation 
frequency occurred in the distal regions of the stem implant (GZ 3-5) while the 
damage also increased, indicating the decrease in porosity is due to the 
increased remodeling due to damage occurring in these regions. 
 
Figure 3-11 shows the activation frequency in the seven different Gruen zones for the 
total hip replacement six years postoperatively. 
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For the articular surface replacement the BVF maintained the levels seen 
from the validation run.  All GZ BVF changes remained under 2% and can been 
seen in Figure 3-12. 
 
Figure 3-12 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the articular surface replacement six years postoperatively.  The 
reference BVF baseline is taken from the day of surgery. 
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Damage levels in GZ 1 increased rapidly throughout all six years 
postoperatively, seen in Figure 3-13, while the other GZ didn’t show any 
significant change. 
 
Figure 3-13 shows the postoperative damage change in the seven different Gruen zones 
for the articular surface replacement six years postoperatively. 
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Overall, activation frequency only showed a slight increase in GZ 1 over 
the six year period, seen in Figure 3-14.  The sharp increase in damage, and 
relatively stable porosity and activation frequency suggest the damage is a result 
of increased strains and the mechanical stimulus. 
 
Figure 3-14 shows the activation frequency in the seven different Gruen zones for the 
articular surface replacement six years postoperatively. 
3.3. Preoperative Alendronate Effects 
Implementing Alendronate treatment one year preoperatively for the total 
hip replacement model led to an increased BVF of 6% in GZ 1 at the end of the 
preoperative period, seen in Table 3-1.  Other GZ didn’t experience a significant 
change. 
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Table 3-1 shows the preoperative end state porosity change for the total hip replacement 
between no Alendronate treatment and one year of Alendronate treatment. 
THR Preoperative 
  BVF (%)   
Gruen Zone No Treatment Treatment % Difference 
1 55% 49% 6% 
2 6% 5% 0% 
3 5% 5% 0% 
4 6% 7% 0% 
5 8% 9% -1% 
6 11% 10% 1% 
7 6% 6% 0% 
 
Alendronate treatment one year preoperatively with the articular 
surface replacement led to an increased BVF of 11% in GZ 1 at the end of 
the preoperative period, with smaller increases in all other regions as well, 
seen in Table 3-2. 
Table 3-2 shows the preoperative end state porosity change for the articular surface 
replacement between no Alendronate treatment and one year Alendronate treatment. 
ASR Preoperative 
  BVF (%)   
Gruen Zone No Treatment Treatment % Difference 
1 57% 46% 11% 
2 7% 6% 1% 
3 7% 6% 1% 
4 7% 6% 1% 
5 8% 6% 2% 
6 12% 9% 3% 
7 7% 6% 2% 
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3.4. Postoperative THR Alendronate Treatment Effects 
Continuous Alendronate treatment starting one day postoperatively and 
lasting for all six years resulted in constant BVF gains for GZ 1 seen in Figure 3-
15.  At the end of six years, GZ 1 had gained 23% BVF.  The only other region to 
show gains was GZ 6 at 2%.  Gruen zone 7 lost about 3% BVF while every other 
region lost less than 1% BVF. 
 
Figure 3-15 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the total hip replacement six years postoperatively with continuous 
Alendronate treatment. The reference BVF baseline is taken from the day of surgery. 
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Continuous treatment for 6 years postoperatively curbed damage across 
all GZ by year three as seen in Figure 3-16.  This is due in part to the decrease 
in resorption area caused by Alendronate, which helps improve bone balance, 
decreasing the microdamage further.  This increased bone balance increases 
bone volume, and the strain and mechanical stimulus decline, decreasing 
damage formation.  The diminished mechanical stimulus also increased 
remodeling activity over time due to the disuse response. 
 
Figure 3-16 shows the postoperative damage change in the seven different Gruen zones 
for the total hip replacement six years postoperatively with continuous Alendronate 
treatment. 
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Activation frequency remained relatively the same across GZ 2-6, while 
GZ 1 showed slight gains and GZ 7 increased the most as seen in Figure 3-17.  
The increase in activation frequency of GZ 7 and decrease in damage over the 
six years still show the prevalence of stress shielding. 
 
Figure 3-17 shows the activation frequency in the seven different Gruen zones for the 
total hip replacement six years postoperatively with continuous Alendronate treatment. 
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For a total hip replacement with Alendronate treatment starting one day 
postoperatively and lasting one year, BVF loss was not as severe as the non 
treated model.  Significant BVF reduction occurred after treatment had 
terminated in year one.   At the end of six years, a decrease in BVF for GZ 1 
reached 26% and BVF reached a 7% reduction in GZ 5 as seen in Figure 3-18. 
 
Figure 3-18 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the total hip replacement six years postoperatively with one year 
postoperative Alendronate treatment.  The reference BVF baseline is taken from the day 
of surgery. 
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Damage in GZ 7 decreased throughout the six year postoperative period 
while damage in GZ 1 slightly increased as seen in Figure 3-19.  The first year 
saw damage peak for GZ 2-6 while it leveled off starting in year two. 
 
Figure 3-19 shows the postoperative damage change in the seven different Gruen zones 
for the total hip replacement six years postoperatively with one year postoperative 
Alendronate treatment. 
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Activation frequency for GZ 1 and 7 increased during the first year while 
all other GZ decreased as seen in Figure 3-20.  During the second year, only GZ 
1 decreased in activation frequency and by year three the activation frequency 
was stable for all GZ.  Sharp increases in activation frequency with concurrent 
decreases in damage suggest some level of stress shielding for all regions but 
GZ 1. 
 
Figure 3-20 shows the activation frequency in the seven different Gruen zones for the 
total hip replacement six years postoperatively with one year postoperative Alendronate 
treatment. 
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Using the preoperative Alendronate treatment for one year combined with 
one year postoperative Alendronate treatment, only GZ 1 shows significant 
change with an 8% BVF increase over a no treatment scenario at the end of one 
year as can be seen in Figure 3-21.  After treatment one year postoperatively, 
GZ 7 has reduced BVF by about 29% and GZ 5 has reduced BVF by about 6%. 
 
Figure 3-21 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the total hip replacement six years postoperatively starting Alendronate 
treatment one year preoperative and ending one year postoperative.  The reference BVF 
baseline is taken from the day of surgery without preoperative treatment to visually 
compare the differences at postoperative time 0 with pretreatment. 
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Damage levels after one year postoperatively start to increase constantly 
in GZ 1 as seen in Figure 3-22.  In all other regions, damage remains fairly 
constant after one year.  During the first year, only GZ 7 sees a decrease in 
damage. 
 
Figure 3-22 shows the postoperative damage change in the seven different Gruen zones 
for the total hip replacement six years postoperatively starting Alendronate treatment one 
year preoperative and ending one year postoperative. 
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Activation frequency for GZ 1 and 7 increased during the first year while 
all other GZ exhibited decreased activation frequency as seen in Figure 3-23.  
During the second year, GZ 1 decreased in activation frequency, GZ 6 stayed 
about the same, and all other GZ exhibited increased activation frequency.  The 
first year GZ 7 increased in activation frequency while decreasing in damage, 
demonstrating stress shielding.   After the second year, GZ 7 saw a gradual 
decrease in activation frequency. 
 
Figure 3-23 shows the activation frequency in the seven different Gruen zones for the 
total hip replacement six years postoperatively starting Alendronate treatment one year 
preoperative and ending one year postoperative. 
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3.5. Postoperative ASR Alendronate Treatment Effects 
Continuous Alendronate treatment for six years postoperatively with the 
articular surface replacement led to an increase of BVF of 26% for GZ 1 by the 
end of the six years as seen in Figure 3-24.  An increase in BVF of 3% was also 
seen in GZ 6.  All other GZ remained stable throughout the six year period.  
 
Figure 3-24 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the articular surface replacement six years postoperatively with 
continuous Alendronate treatment.  The reference BVF baseline is taken from the day of 
surgery. 
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The continuous treatment helped curb damage levels across all GZ by 
year three, seen in Figure 3-25.  Damage in GZ 1 peaked in year one and 
asymptotically decreased towards zero. 
 
Figure 3-25 shows the postoperative damage change in the seven different Gruen zones 
for the articular surface replacement six years postoperatively with continuous 
Alendronate treatment. 
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Activation frequency over the six years increased for GZ 1 and also 
increased more gradually for GZ 6 as seen in Figure 3-26.  All other GZ 
experienced little activation frequency change.  
 
Figure 3-26 shows the activation frequency in the seven different Gruen zones for the 
articular surface replacement six years postoperatively with continuous Alendronate 
treatment. 
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Postoperative BVF changes with treatment starting the day of surgery and 
ending after one year remained pretty stable throughout the six year period as 
seen in Figure 3-27.  Initially GZ 1 showed a 3% increase in BVF but declined to 
1% at the end of six years.  All other GZ experienced losses of less than 2% over 
the six year period. 
 
Figure 3-27 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the articular surface replacement six years postoperatively with one year 
postoperative Alendronate treatment.  The reference BVF baseline is taken from the day 
of surgery. 
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Damage levels for the one year postoperative articular surface 
replacement model stayed constant with the exception of GZ 1, as seen in 
Figure 3-28.  Damage levels in GZ 1 gradually increased over the entire six year 
period. 
 
Figure 3-28 shows the postoperative damage change in the seven different Gruen zones 
for the articular surface replacement six years postoperatively with one year 
postoperative Alendronate treatment. 
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Activation frequency also remains pretty constant for the entire six years 
after one year postoperative Alendronate treatment to the articular surface 
replacement model, as seen in Figure 3-29. 
 
Figure 3-29 shows the activation frequency in the seven different Gruen zones for the 
articular surface replacement six years postoperatively with one year postoperative 
Alendronate treatment. 
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Using the preoperative Alendronate treatment for one year and continuing 
treatment for one year postoperatively mainly affected the BVF in GZ 1 seen in 
Figure 3-30.  The BVF for GZ 1 increased to 13% in year one before decreasing 
to less than a 1% gain over the six year period.  All other GZ had a decrease in 
BVF over the six year period of less than 2%. 
 
Figure 3-30 shows the postoperative bone volume fraction changes in the seven different 
Gruen zones for the articular surface replacement six years postoperatively starting 
Alendronate treatment one year preoperative and ending one year postoperative.  The 
reference BVF baseline is taken from the day of surgery without preoperative treatment 
to visually compare the differences at postoperative time 0 with pretreatment. 
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Damage levels for this scenario remained constant throughout the six 
years for GZ 2-7 as seen in Figure 3-31.  A constant increase in damage for GZ 
1 started after year one and continued for the whole simulation. 
  
Figure 3-31 shows the postoperative damage change in the seven different Gruen zones 
for the articular surface replacement six years postoperatively starting Alendronate 
treatment one year preoperative and ending one year postoperative. 
72 
 
Activation frequency for the one year preoperative Alendronate treatment 
with one year postoperative treatment stayed fairly constant for most GZ seen in 
Figure 3-32.  A small decrease for GZ 1 happened after year one but then 
remained constant for the following years. 
 
Figure 3-32 shows the activation frequency in the seven different Gruen zones for the 
articular surface replacement six years postoperatively starting Alendronate treatment 
one year preoperative and ending one year postoperative. 
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4. Discussion 
Bisphosphonate drugs such as Alendronate have recently been 
administered in conjunction with a hip arthroplasty [10, 11].  These drugs are 
being used in an attempt to prevent the bone loss in the femur as a result of the 
implant and surgical procedure.  In this study we attempted to directly compare 
the long term effects bisphosphonates had on both total hip and articular surface 
replacements using a 3-D finite element model of the femur with an adaptive 
bone remodeling algorithm incorporating Alendronate treatment.  Our results 
showed the success of creating a long term total hip and articular surface 
replacement model treated with Alendronate. 
  Clinically, with dual-energy X-ray absorptiometry measurements, it’s 
been shown most bone loss occurs in the first few months after THR surgery and 
reveals little change after the first postoperative year.  Alendronate treatment 
could change this effect. 
In one study mentioned earlier (section 3.1), Arabmotlagh et al. [63] 
monitored patients for one year postoperatively that had undergone a total hip 
replacement surgery and measured the bone mineral density (BMD) change 
using dual-energy x-ray absorptiometry (DEXA). In this experiment one group 
received a placebo, another group received 10mg/day of oral Alendronate for ten 
weeks, and another group received 20mg/day for five weeks. After one year, the 
group with the placebo helped validate our model since there were no significant 
differences when compared to our results.  However, this clinical experiment also 
lasted a total of six years.  When comparing the placebo group to our computer 
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model results after six years, GZ 1, GZ 2, GZ 6, and GZ 7 were statistically 
similar while GZ 3 – 5 had significant differences (p-values = 0.035, 0.012, 0.001 
respectively) as seen in Figure 4-1. 
 
Figure 4-1 shows a comparison between results obtained clinically by Arabmotlagh et al. 
[63] and our experimental data six years postoperatively for a THR with no Alendronate 
treatment.  Statistical similarities were found  in GZ 1, GZ 2, GZ 6, and GZ 7 and 
significant differences were seen in GZ 3 (p-value = 0.035), GZ 4 (p-value = 0.012), and 
GZ 5 (p-value = 0.001). 
    The results of the experimental treatment group that received the 10 
mg/day for ten weeks were fairly consistent to the results from this computational 
study after one year of treatment.  At the end of one year, the percent change of 
BMD of our experimental study was consistent with the clinical results, with one 
significant difference in GZ 7 (p-value = 0.004), seen in Figure 4-2.  This 
discrepancy is largely due to our model still being under Alendronate effects at 
this time (one year). 
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Figure 4-2 shows a comparison between results obtained clinically by Arabmotlagh et al. 
[63] and our experimental data one year postoperatively for a THR with one year 
postoperative Alendronate treatment.  All regions were statistically similar except one 
significant difference seen in GZ 7     (p-value = 0.004). 
After six years with the postoperative Alendronate treatment scenarios by 
Arabmotlagh et al. compared with the one year treatment from ours, there were 
no significant differences found, as can be seen in Figure 4-3. 
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Figure 4-3 shows a comparison between results obtained clinically by Arabmotlagh et al. 
[63] and our experimental data six years postoperatively for a THR with one year 
postoperative Alendronate treatment. 
Another study by Nishioka et al. [61] in which we used to validate our 
model also evaluated the effects of Alendronate on bone loss caused by stress 
shielding after total hip arthroplasty in Japanese patients.  The Alendronate was 
administered orally at 5 mg/day for one year and measured a change in bone 
mineral density ratio using DEXA scans.  All model results after one year were 
within the range of these clinical results as seen in Figure 4-4.  Again, vvisual 
inspection of the standard deviation results obtained by Nishioka et al. [61] were 
used for this determination since the values were not given. 
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Figure 4-4 shows a comparison between results obtained clinically by Nishioka et al. [61] 
and our model data one year postoperatively for a THR with one year postoperative 
Alendronate treatment. 
Comparisons to both studies by Arabmotlagh et al. [63] and Nishioka et al. 
[61] showed significant similarities clinically to the results of the current study.  
While treatment scenarios, patient bone anatomies, and differing hip implants are 
some of the differences between our study results and the clinical results, we are 
still able to gain a confidence our models are working and predicting bone 
changes correctly.  The total hip replacement results acted as a validation for our 
model and led to an acceptance for our surface replacement results.  Figures 
showing the BVF distribution on the bone can be seen in Appendix E for one 
year postoperative and in Appendix F for six years postoperative. 
An interesting observation occurs between the runs with preoperatively 
treated bone to the bone with no preoperative treatment.  While initially bone with 
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the pretreatment has a higher BVF, especially in GZ 1, after postoperative 
treatment the change in BVF between the scenarios was minimal.  Damage on 
the other hand has some significant long term differences.  After the conclusion 
of Alendronate treatment, the pretreated bone had a greater increase of damage 
over the six year period with both types of implants for GZ 1.  At the end of the 
six years, the damage was about double that of the bone treated at the start of 
surgery in GZ 1 with little change in other GZs.  The implications here are that 
there is no benefit to pretreating a patient with Alendronate for bone in the Gruen 
zones, and that it might actually be worse in the long run for fracture risk in GZ 1 
due to the damage buildup.  This could be due to increased time exposure before 
stopping treatment causing a more brittle bone susceptible to damages after one 
year when both the loads are returned to normal and treatment stops at the same 
time. 
At the end of six years we can draw some comparisons between all the 
different scenarios we ran.  With regards to BVF, there is little change between 
one year preoperative to one year postoperative Alendronate treatment and one 
year postoperative Alendronate treatment for a specific implant type, while both 
treatment scenarios seem to increase the BVF over no treatment.  However, 
when comparing between different implant types, the ASR had higher BVF for all 
GZs. This is expected since the GZs are defined around a THR stem and for an 
ASR, the GZ are distal to the implant.  These comparisons can be seen in Figure 
4-5.  
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Figure 4-5 shows the bone volume fraction (BVF) change comparisons after six years for 
the major treatment scenarios.  The reference BVF baseline is taken from the day of 
surgery without preoperative treatment. 
 After six years postoperative time, we could also compare damages 
between the different Alendronate treatment scenarios.  Pretreatment for both 
the THR and ASR had a large impact on the damages in GZ 1.  Damages in the 
distal GZs were higher with the THR while damages in the proximal GZs had 
more damage with an ASR given the same treatment scenario.  Treatment 
scenarios with the THR seemed to decrease the damage for GZ 3, 4, and 5. 
These damage comparisons can be seen in Figure 4-6. 
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Figure 4-6 shows the damage for the major treatment scenarios after six years. 
 One finding by Deuel et al. [34] showed high levels of strain adjacent to 
the rim of the ASR, similar to Watanabe et al [64].  In the study by Watanabe et 
al. stress shielding was observed in the femoral neck, leading to a suggestion 
that the losses in bone density due to stress shielding in combination with areas 
of stress concentration around the implant could lead to fracture following hip 
resurfacing.  With our simulations, the effects of Alendronate treatment scenarios 
could be compared for the area around the ASR rim as well.  Looking at the 
strains without any Alendronate treatment we can see a sharp increase right after 
implantation with the values steadying about three years postoperative.  With 
treatment starting the day of surgery the strain lowers, and with pretreatment 
strain lowers even more, closer to normal levels.  The differences in strain 
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around the ASR rim can be seen in Figure 4-7 and pictures of the strain can be 
seen in Appendix F. 
 
Figure 4-7 shows the differences in strain adjacent to the ASR rim for the different 
treatment scenarios. 
Damage follows a similar pattern to the strain with the different treatment 
scenarios seen in Figure 4-8.  Alendronate treatment drastically reduces the 
damage level when being compared to no treatment.  Pretreating with 
Alendronate seems to show the best damage reduction value. 
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Figure 4-8 shows the differences in damage adjacent to the ASR rim for the different 
treatment scenarios. 
Interestingly, the BVF adjacent to the rim increased with Alendronate 
treatment.  Pretreating also seemed to increase the BVF even more, as seen in 
Figure 4-9.  With this information, it seems as if the Alendronate helped even out 
the imbalance of bone resorption to reformation.  This helped decrease the 
damage in the rim area and maintain lower strain values with the increase of 
bone density in the area. 
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Figure 4-9 compares the BVF percentage adjacent to the ASR rim for the different 
treatment scenarios. 
Previous models incorporating this bisphosphonate code [48, 49] 
maintained continuous treatment and never looked at the effects after treatment 
had stopped.  The bisphosphonate code is either turned on or off, with no 
lingering effects.  However, drugs still remain in the body even after a person has 
stopped the intake.  The half life of Alendronate in humans is estimated to be 
about ten years in length [65].  The current code for bisphosphonates needs to 
add in a function over time related to the potency to decrease the effects of 
bisphosphonates to correspond with the half life.  While the long term results still 
fit to clinical numbers, the simulation could become more accurate with this 
implemented. 
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There are also some limitations to the bone model itself in our study.  A 
model from the CT scan of the cadaveric bone had an unknown loading history, 
and comparisons between the clinical and experimental bone density changes 
occurred under estimated loading conditions which may not have been 
representative of the individual.  Also, the identical loading conditions were used 
for the models of both hip resurfacing and total hip replacements, even though 
the patient population for resurfacing is generally younger and more active.  
Patterns of bone loss were consistent with other clinical and computational 
studies however.  A limitation with the user material subroutine to our model is 
that bone remodeling is a complex process affected by skeletal loading as well 
as metabolic and hormonal activities and these factors aren’t accounted for.  
Loading changes from the native state following surgery is the most likely factor 
contributing to the remodeling rates though.  The implants in the model are also 
fully bonded to the surrounding bone immediately following implantation, which 
has the potential of allowing greater load transfer to the proximal aspect of the 
femur than occurs for the total hip replacement clinically.   
Even with all these limitations we were able to show the pretreatment of 
Alendronate compared to starting treatment the day of surgery may not have 
much of an impact on long term bone density for the Gruen Zones.  Damage 
seems to double with pretreatment compared to no treatment for GZ 1.  The 
resurfacing implant caused more damage to the proximal GZs while the total hip 
replacement caused more damage to the distal zones around the implant stem.  
When looking around the resurfacing rim however, pretreatment seems to show 
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big changes in the damage, strain, and bone density values when compared to 
no treatment and treatment starting the day of surgery.  The implication is that 
pretreatment may help prevent femoral neck fracture.   
Future experiments might want to investigate if offsetting the termination 
of Alendronate and the return of full force loads would help decrease the damage 
accumulation rate.  Also, the addition of the Alendronate half life to better 
simulate long term drug effects on the bone might provide higher accuracy.  
Additionally, modeling hormonal effects and implementing them into the user 
material code could improve the model simulations.  A more complete muscle 
force set could be added to the femur model as well.  While the primary muscles 
involved in stress patterns for the proximal aspect of the femur were used, other 
muscles such as the quadriceps and iliotibial band have been shown to have 
more of an effect on diaphyseal strains [66].  The loading conditions for the 
model were also applied under an ideal implant state while implanting into an 
actual human will not have the perfect surgical positioning, for example the 
implant may not always have the same neck length as the native femur.  
Diseases like cancer could also be factored into the model in the future.  
Radiation effects on bone remodeling and bone properties could be observed as 
well.  As newer drugs are produced and more information about remodeling is 
discovered, these effects can then be modeled and compared using this 
simulation.  The user material subroutine could also be used for other bones with 
implants to determine similar effects with bisphosphonate treatments and 
whether certain treatment scenarios provide any long term benefits. 
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Appendix A  User Subroutine 
      subroutine sdvini(statev,coords,nstatv,ncrds,noel,npt, 
     * layer,kspt) 
c 
      include '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc' 
c 
      character*80 fname 
      dimension statev(nstatv),coords(ncrds) 
      dimension jelarr(110000,2),sdvarr(110000,105) 
      integer kflag 
      save kflag,sdvarr,jelarr 
c 
c      write(*,*) 'kflag = ', kflag 
      if (kflag.eq.0) then       
c 
         fname='/home/thryce/bmu/taperloc_preop_bis.txt' 
         intpts=106124 
c 
         open(unit=300,file=fname,status='old') 
c 
c 
         do i=1,intpts 
            read(300,310) jelarr(i,1),jelarr(i,2),(sdvarr(i,j),j=1,105) 
 310        format(i5,1x,i2,1x,4f12.9,1x,e12.6,1x,3f10.6,1x,100f9.6) 
         end do      
c 
         kflag=1 
         write(*,*) 'Finished reading .txt file' 
      end if 
c 
      if (noel.le.26531) then 
         if ((noel.gt.19694).and.(noel.le.26531)) then 
            krownum=((noel-2)*4)+npt 
         else if (noel.le.19694) then    
            krownum=((noel-1)*4)+npt 
         end if 
c       
         do k2=1,105 
            statev(k2)=sdvarr(krownum,k2) 
         end do 
      else 
c 
c  initialize porosity 
c 
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      statev(1)=0.05 
c      statev(1)=0.20 
c 
c  initialize minimum principal strain for first,  
c                                second, and third steps 
c 
      statev(2)=0.0 
      statev(3)=0.0 
      statev(4)=0.0 
c 
c  initialize damage potential 
c 
      statev(5)=0.0 
c 
c  initialize equilibrium damage 
c 
      statev(6)=0.03662944 
c 
c  initialize number of refilling and resorbing BMUs 
c 
      statev(7)=0.0 
      statev(8)=0.0 
c 
c  initialize activation frequency for trif days 
c 
      do k=9,nstatv 
         statev(k)=0.00670 
      end do 
      end if 
      close (unit=300) 
      return 
      end 
c 
c 
c 
c 
c 
      subroutine umat(stress,statev,ddsdde,sse,spd,scd, 
     * rpl,ddsddt,drplde,drpldt, 
     * stran,dstran,time,dtime,temp,dtemp,predef,dpred,bone, 
     * ndi,nshr,ntens,nstatv,props,nprops,coords,drot,pnewdt, 
     * celent,dfgrd0,dfgrd1,noel,npt,layer,kspt,kstep,kinc) 
c 
      include '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc' 
c 
      character*8 bone 
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      dimension stress(ntens),statev(nstatv),ddsdde(ntens,ntens), 
     * stran(ntens),dstran(ntens),props(nprops),s(3),ps(3) 
      integer trif,tr,ti,tf,lstr 
      real kb,kc,kd,kr,nf,nr,nfexist,nrexist,do,sa,modulus,nu, 
     * tstep,minprin,rl1,rl2,rl3,phi,shearmod,bulkmod,lambda,samax, 
     * q,pi,fs,dt,facur,famax1,famax2,fao,rc,rh,dexist,area,ddotform, 
     * ddotrep,dcurrent,fadivsa,fa,ab,ac,qb,qc,phc,qnet,dp,maxprin, 
     * maxmag 
c 
c  elastic properties 
c      write(*,*) 'step = ', kstep 
 
c 
c 
         if (statev(1).lt.0.097267787) then 
            modulus=23440*(1-statev(1))**5.74 
         else 
            modulus=14927*(1-statev(1))**1.33 
         endif 
c  
      nu=props(1) 
c 
c     specify props for titanium 
      if (noel.gt.26531) then 
         modulus=114000 
         nu=0.33 
         spd=3 
         scd=75. 
         sse=0.8 
      end if 
c 
      bulkmod=modulus/(3*(1-2*nu)) 
      shearmod=modulus/(2*(1+nu)) 
      lambda=bulkmod-2*shearmod/3 
c 
c  elastic stiffness 
c 
c 
c        
      ddsdde(1,1)=2*shearmod+lambda 
      ddsdde(2,2)=2*shearmod+lambda 
      ddsdde(3,3)=2*shearmod+lambda 
      ddsdde(4,4)=shearmod 
      ddsdde(5,5)=shearmod 
      ddsdde(6,6)=shearmod 
      ddsdde(1,2)=lambda 
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      ddsdde(1,3)=lambda 
      ddsdde(2,1)=lambda 
      ddsdde(2,3)=lambda 
      ddsdde(3,1)=lambda 
      ddsdde(3,2)=lambda 
c 
c  initialze stress for the current step 
c 
      do k1=1,ntens 
         stress(k1)=0.0 
      end do 
c 
c  calculate stress 
c 
      do k1=1,ntens 
         do k2=1,ntens 
            stress(k2)=stress(k2)+ddsdde(k2,k1)*(stran(k1)+dstran(k1))        
         end do 
      end do 
c 
c  proceed through remodeling algorithm for elements defining bone 
c 
c 
c 
c  calculate minimum and maximimum principle strains 
c 
c  transform current steps to tstep to define first, second, and 
c  third steps of input file 
c  
c  store maximum magnitude principle strain as state variable for each step 
c 
      if (kstep.eq.1) then 
 if (noel.eq.1) then 
   if (npt.eq.1) then 
     write(*,*) 'calculating strains' 
   endif 
 endif 
      endif 
c 
c 
      if (noel.le.26531) then            
         do k1=1,ntens 
            s(k1)=stran(k1)+dstran(k1) 
         end do 
         lstr=2                                                                                                                      
         call sprinc(s,ps,lstr,ndi,nshr)                                                                                            
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         if (abs(ps(1)).ge.abs(ps(2))) then 
            maxmag=ps(1) 
         else 
            maxmag=ps(2) 
         endif 
c 
         tstep=abs((real(kstep))/3-int(kstep/3)) 
         if ((tstep.gt.0.2).and.(tstep.lt.0.5)) then  
            statev(2)=maxmag 
         else if ((tstep.gt.0.5).and.(tstep.lt.0.8)) then 
            statev(3)=maxmag 
         else if (tstep.lt.0.2) then 
            statev(4)=maxmag 
         endif 
c 
c 
c 
c 
c  specify activation frequency at equilibrium 
         fao=0.00670 
c         
c 
c  calculate time for resorptive phase of remodeling cycle, tr 
c  calculate time for reversal phase of remodeling cycle, ti 
c  calculate time for refilling phase of remodeling cycle, tf 
c  calculate total time of remodeling cycle, trif 
c 
         tr=25 
         ti=5 
         tf=64 
         trif=tr+ti+tf 
c 
c  initialize the existing number of refilling and resorbing BMUs 
c  specify existing number of refilling and resorbing BMUs 
c 
      if (kstep.eq.1) then 
 if (noel.eq.1) then 
   if (npt.eq.1) then 
     write(*,*) 'calculating BMUs' 
   endif 
 endif 
      endif 
c 
c 
         if (kstep.eq.1) then 
            statev(7)=fao*tf 
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            statev(8)=fao*tr 
         endif 
         nfexist=statev(7) 
         nrexist=statev(8) 
c 
c ******************************************************** 
c 
c  proceed through porosity update after the third step 
c 
c 
c 
         if ((kstep.ne.1).and.(tstep.lt.0.2)) then 
c 
c  calculate damage potential 
c  store damage potential as state variable 
c  calculate rate of damage formation 
c  calculate rate of damage repair 
c  calculate current day damage 
c  store current day damage as state variable 
c 
c  specifiy equilibrium damage 
c  initialize existing damage 
c  specify existing damage  
c   
            do=0.03662944 
            dexist=statev(6) 
c 
c  specify coefficients for damage formation equation and 
c                              activation frequency equations  
c 
c           kd=40.2 
            kd=185000. 
            kr=-1.6 
c           kb=13000000. 
            kb=65000000000. 
c           kc=0.0000004325 
            kc=0.0000000000938 
c             
c 
c  specify loading rate for load case 1, rl1, load case 2, rl2, 
c                                             and load case 3, rl3 
c  specify exponent for damage formation equation 
c 
     if (kstep.le.270) then 
               rl1=2000. 
               rl2=2000. 
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               rl3=16. 
            else if ((kstep.le.1095).and.(kstep.gt.270)) then 
               rl1=2250. 
               rl2=2250. 
               rl3=18. 
            else 
               rl1=2500. 
               rl2=2500. 
               rl3=20. 
            endif             
c           q=2.89 
            q=4 
c 
c 
c  specify value for pi 
c  specify repair specificity factor 
c  specify time step  
c 
            pi=3.1415926535897932385 
            fs=5.0 
            dt=1.0 
c             
c  specify current day activation frequency 
c  specify max activation frequency/max specific surface area          
c 
            facur=statev(9) 
c           famax1=2.15 
            famax1=0.50 
c           famax2=4.15 
            famax2=1.15 
            samax=4.1905 
c  
c  specify cement line radius 
c  specify haversian radius 
c      
            rc=0.095 
            rh=0.020 
c             
c             
c 
            phi=((abs(statev(2)))**q)*rl1+((abs(statev(3)))**q)*rl2 
     *                                       +((abs(statev(4)))**q)*rl3 
            statev(5)=phi 
            if (statev(1).le.0.20) then 
               area=pi*rc**2 
            else 
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               area=0.5*pi*rc**2 
            endif 
            ddotform=kd*phi 
            ddotrep=dexist*facur*area*fs 
            dcurrent=dexist+(ddotform-ddotrep)*dt 
     if (dcurrent.ge.800) then 
        dcurrent=800 
     endif 
            statev(6)=dcurrent 
c 
c 
c  update current activation frequency 
c  calculate specific surface area 
c  add in potency for bisphosphonate treatment 
c  update activation frequency by a reduction of P 
c 
            fadivsa=(fao*(famax1/samax))/(fao+(famax1-fao) 
     *                     *exp(kr*famax1*(dcurrent-do)/do)) 
            if (dcurrent.lt.do) then 
               fadivsa=(fao/samax)*(dcurrent/do) 
            endif 
            sa=((((28.8*statev(1)-101)*statev(1)+134)*statev(1) 
     *                     -93.9)*statev(1)+32.3)*statev(1) 
c            if (phi.lt.0.000000865) then 
            if (phi.lt.0.0000000001875) then 
               fadivsa=fadivsa+(famax2/samax)/(1+exp(kb*(phi-kc))) 
            endif 
     fa=fadivsa*sa 
     if (kstep.le.1092) then 
        P=1*(1-exp(-5.0*nrexist)) 
        fa=(1-P)*fadivsa*sa 
     endif 
c 
c  update activation frequency history 
c 
            do k1=trif+9,10,-1 
               statev(k1)=statev(k1-1) 
            end do 
c 
c  store current activation frequency as state variable 
c 
            statev(9)=fa 
c 
c  add in bisphosphonate reduction to trabecular bone 
c  calculate daily amount of bone added per refilling BMU 
c  calculate daily amount of bone removed per resorbing BMU 
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c  include decreased resorption after specified time 
c  include less refilling on trabecular surfaces in disuse 
c 
            ac=area 
               if (kstep.le.1092) then 
                  if (statev(1).gt.0.20) then 
                    ac=area*(10/13) 
                  endif 
               endif 
            if (statev(1).le.0.20) then 
               area=pi*(rc**2-rh**2) 
            endif 
            ab=area 
            qb=ab/tf 
     qc=ac/tr 
            if (statev(1).gt.0.20) then 
               if (phi.lt.0.0000000001875) then 
                  qb=(0.5+0.5*phi/0.0000000001875)*ab/tf  
               endif 
            endif 
c 
c  calculate number of refilling BMUs for current day 
c  calculate number of resorbing BMUs for current day 
c  store number of refillilng and resorbing BMUs as state variables 
c 
            nf=nfexist+(statev(tr+ti+9)-statev(trif+9))*dt 
            nr=nrexist+(statev(9)-statev(tr+9))*dt 
            if (nf.lt.0.0) then 
               nf=0.0 
            endif 
            if (nr.lt.0.0) then 
               nr=0.0 
            endif 
            statev(7)=nf 
            statev(8)=nr 
c 
c  calculate net amount of bone added per day 
c 
            phc=0.04432132964 
            qnet=(qb*nf)-(qc*nr) 
            if (statev(1).le.0.20) then 
               qnet=(qb*nf)-(1-phc)*(qc*nr) 
            endif 
c  
c  calculate change in porosity 
c  update porosity 
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c 
            dp=-qnet*dt 
            statev(1)=statev(1)+dp 
c 
c  specify limits for porosity 
c  check porosity against limits 
c  specify state variables to plot 
c 
c       write(*,*) 'delta porosity = ', dp 
c write(*,*) 'final porosity = ', statev(1) 
c write(*,*) 'activation freq = ', statev(9) 
c write(*,*) 'damage = ', statev(6) 
            ulim=0.99 
            blim=0.05 
            if (statev(1).ge.ulim) then 
               statev(1)=ulim 
            else if (statev(1).le.blim) then 
               statev(1)=blim 
            endif 
         endif 
         spd=statev(1) 
         sse=statev(9) 
         scd=statev(6)*(0.95/(1-statev(1))) 
c         spd=statev(5) 
c         sse=modulus 
c         scd=statev(6) 
c         spd=statev(2)  
c         sse=statev(3) 
c         scd=statev(4) 
      endif       
      return 
      end 
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Appendix B  Extracting Results 
C============================================================
========= 
C 
C  This program extracts state variables from a .fil file 
C   
C  Reference Abaqus Standard User's Manual Volume 1 Sections 5.1.2,3 
C  and Abaqus Example Problems Manual Section 11.1.3 V6.3  
C============================================================
========= 
C 
C Define variables and arrays 
C 
      SUBROUTINE ABQMAIN 
      INCLUDE '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc' 
      CHARACTER*80 FNAME, FOUT 
      DIMENSION STVAR(200) 
      DIMENSION ARRAY(513),JRRAY(NPRECD,513),LRUNIT(2,1) 
      EQUIVALENCE (ARRAY(1),JRRAY(1,1)) 
C 
C Name output file and results file 
C 
      WRITE(*,*) 'ENTER OUTPUT FILENAME' 
      READ(*,*) FOUT 
      WRITE(*,*) 'ENTER .FIL FILENAME WITHOUT .FIL EXT' 
      READ(*,*) FNAME 
C      FNAME='' 
C 
C Open output file 
C 
      OPEN(UNIT=400,FILE=FOUT,STATUS='NEW') 
C 
C Intiliaze ABAQUS interface with FORTRAN 
C See Abaqus manual section 5.1.3 version 6.3 
C 
      NRU=1 
      LRUNIT(1,1)=8 
      LRUNIT(2,1)=2 
      LOUTF=0 
      CALL INITPF(FNAME,NRU,LRUNIT,LOUTF) 
      JUNIT=8 
      CALL DBRNU(JUNIT) 
C    
C Read records from the results file (*.fil). 
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C 
         DO 100 K1=1,99999999 
            CALL DBFILE(0,ARRAY,JRCD) 
C               write(*,*) 'jrcd', jrcd 
            IF (JRCD.NE.0) GO TO 110 
C 
C Get record key for current line. 
C 
            KEY=JRRAY(1,2) 
C           write(*,*) 'KEY= ',KEY 
C 
C Retrieve element and int point # from element header record (key=1) 
C See Abaqus manual section 5.1.2 version 6.3 for keys 
C 
            IF (KEY.EQ.1) THEN 
               JEL=JRRAY(1,3) 
               JPNT=JRRAY(1,4) 
C 
C Retrieve solution dependent state variables (key=5) 
C 
            ELSE IF (KEY.EQ.5) THEN 
               DO I=1,105 
                  STVAR(I)=ARRAY(I+2) 
               END DO 
               WRITE(400,80) JEL,JPNT,(STVAR(J),J=1,105) 
 80            FORMAT(I5,1X,I2,1X,4F12.9,1X,E12.6,1X,3F10.6,1X,100F9.6)  
            END IF               
 100     CONTINUE 
 110     CONTINUE 
C 
      CLOSE (UNIT=400) 
      STOP 
      END 
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Appendix C  Extracting File 
C============================================================
========= 
C 
C  The program extracts the state variables from a bone adaptation 
C  model for given region per 75 days into a text file. 
C 
C============================================================
========= 
C 
C Define variables and arrays 
C 
      INCLUDE '/usr/apps/abaqus/6.7-3/site/aba_param_dp.inc' 
      CHARACTER*80 FNAME, OUTNAME 
      INTEGER NOELEM, JELDUM, JCT, INCSTART, INCSTOP, LAST 
      REAL NOSTV 
      DIMENSION JELEM(1000), STVAR(1000), AVGSTV(1000) 
      DIMENSION ARRAY(513),JRRAY(NPRECD,513),LRUNIT(2,1) 
      EQUIVALENCE (ARRAY(1),JRRAY(1,1)) 
C 
C Open input file and read in results file, number of elements in group 
C of interest, and list of element numbers making up group. 
C 
      OPEN(UNIT=300,FILE='taperlocpostopgruen1.isv',STATUS='OLD') 
      READ(300,500) FNAME 
      PRINT *, FNAME 
      READ(300,500) OUTNAME 
      PRINT 502, 'Output file is ', OUTNAME 
      READ(300,501) INCSTART 
      PRINT 503, 'Start increment is ',INCSTART 
      READ(300,501) LAST 
      PRINT *, LAST 
      READ(300,501) NOELEM       
      PRINT 503, 'Number of Elements in Group = ', NOELEM 
      DO 15 L=1,NOELEM  
         READ(300,501) JELDUM 
         JELEM(L)=JELDUM 
 15   CONTINUE 
 500  FORMAT(A) 
 501  FORMAT(I) 
C 
C Open output file 
C 
      OPEN(UNIT=400,FILE=OUTNAME,STATUS='NEW') 
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C 
C Check to see if input file was read correctly. 
C   
 502  FORMAT(A20,A20) 
 503  FORMAT(A30,I) 
      DO 16 L=1,NOELEM  
         PRINT *, 'ELEM #', JELEM(L) 
 16   CONTINUE 
C 
C Intiliaze ABAQUS interface with FORTRAN 
C 
      NRU=1 
      LRUNIT(1,1)=8 
      LRUNIT(2,1)=2 
      LOUTF=0 
      CALL INITPF(FNAME,NRU,LRUNIT,LOUTF) 
      JUNIT=8 
      CALL DBRNU(JUNIT) 
C 
C  Heading for output file 
C 
      WRITE (400,104) 'step', 'fa', 'porosity', 'damage' 
 104  FORMAT(1X, A4, T6, A7, T17, A9, T27, A8)    
C 
C Call the desired steps from which data is extracted. 
C 
C Loop through calls of step number (e.g. 150,300,450,600) 
C 
      NSTEP=INCSTART 
      INCSTOP=LAST 
      NINC=0 
      DO 2000 J10=1,50 
         IF (NSTEP.GT.INCSTOP) GO TO 2001 
         K=1 
         JCT=0 
         CALL POSFIL(NSTEP,NINC,ARRAY,JRCD) 
C         WRITE(*,*) 'JRCD = ', JRCD 
         WRITE(*,*) 'STEP ', NSTEP 
C 
C Set state variables equal to zero. 
C 
         NOSTV=3 
         DO J=1,NOSTV 
            STVAR(J)=0.0 
         END DO 
C 
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C Read records (element, state variables) from the results 
C file (*.fil).  Cover a maximum of 10 million records. 
C 
         DO 1000 K100=1,10000 
         DO 1000 K1=1,9999 
C                 WRITE(*,*) 'K100 ', K100 
C                 WRITE(*,*) 'K1 ', K1 
            CALL DBFILE(0,ARRAY,JRCD) 
C               write(*,*) 'jrcd', jrcd 
            IF (K.GT.NOELEM) GO TO 1001 
C 
C Get record key for current line. 
C 
            KEY=JRRAY(1,2) 
C            write(*,*) 'KEY= ',KEY 
C 
C Retrieve element number form record line 
C 
            IF (KEY.EQ.1) THEN 
               JEL=JRRAY(1,3) 
               JPT=JRRAY(1,4) 
C 
C 
C 
            ELSE IF (KEY.EQ.14) THEN 
C            write(*,*) 'JEL= ',JEL 
C            write(*,*) 'JELEM= ',JELEM(1) 
               IF (JEL.EQ.JELEM(K)) THEN 
                  DO I=1,NOSTV 
                     STVAR(I)=STVAR(I)+ARRAY(I+2) 
                  END DO 
C                     WRITE(*,*) 'ELEM #', JEL 
C                     WRITE(*,*) 'INTEG #', JPT 
C                     WRITE(*,*) 'ARRAY ',ARRAY(3) 
C                     WRITE(*,*) 'VARIA ',STVAR(1) 
                     K=K+1 
               END IF 
            END IF 
 1000    CONTINUE 
 1001    CONTINUE 
C 
C Calculate the average state variables for all integration points. 
C 
C 
         DO L=1,NOSTV 
            AVGSTV(L)=STVAR(L)/(NOELEM) 
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         END DO 
C 
         WRITE(400,504) NSTEP, (AVGSTV(J),J=1,NOSTV) 
 504     FORMAT(I5,1X,F9.6,1X,F9.6,1X,F9.6) 
         NSTEP=NSTEP+1092 
 2000 CONTINUE 
 2001 CONTINUE 
      CLOSE (UNIT=400) 
      STOP 
      END 
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Appendix D  ISV File 
taperloc_postop 
taperlocpostopgruen12250.txt 
1092 
2184 
20 
19734 
19738 
19877 
20406 
20486 
20497 
20519 
20523 
20529 
20533 
20565 
21104 
21199 
21205 
21240 
21241 
21845 
21948 
21958 
21991 
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Appendix E  One Year Porosity Pictures 
 
Figure  E-1 shows porosity for the total hip replacement one year postoperatively for no 
bisphosphonate treatment (left), treatment starting day of surgery (middle), and treatment 
starting one year preoperatively (right). 
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Figure  E-2 shows porosity for the articular surface replacement one year postoperatively 
for no bisphosphonate treatment (left), treatment starting day of surgery (middle), and 
treatment starting one year preoperatively (right). 
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Appendix F  Six Year Porosity Pictures 
 
 
Figure  F-1 shows porosity for the total hip replacement six years postoperatively for 
treatment starting day of surgery (left) and treatment starting one year preoperatively 
(right). 
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Figure  F-2 shows porosity for the articular surface replacement six years postoperatively 
for treatment starting day of surgery (left), and treatment starting one year preoperatively 
(right). 
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Appendix G  Six Year Strain Pictures 
 
Figure  G-1 shows the  strain adjacent to the articular surface replacement rim six years 
postoperatively for no treatment (top), treatment starting day of surgery (middle), and 
treatment starting one year preoperatively (bottom). 
 
